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Translocations that generate MLL fusion proteins are common causes of human 
acute leukemias. Aberrant target gene activation is the primary driver of MLL-
rearranged leukemogenesis, but the underlying mechanisms remain poorly 
understood. In the present study, we identified two partners of the MLL fusion 
complex, PAFc and CBX8, which can interact with a common MLL fusion protein, 
MLL-AF9, through the N-terminal MLL part and the C-terminal AF9 part, 
respectively. Our data demonstrate that both PAFc and CBX8 are required for 
MLL-AF9-mediated transcriptional upregulation and leukemic transformation. The 
molecular mechanisms for their requirements in the leukemogenic process are 
different. By chromatin immunoprecipitation, we show that PAFc binds at the 
MLL target gene (e.g., Hoxa9 and Meis1) loci in MLL-AF9 leukemic cells. Its 
binding contributes to the recruitment of MLL-AF9 and augments MLL-AF9-
mediated transcriptional activation. In contrast, CBX8 promotes the 
transcriptional activation of MLL-AF9 target genes, not by regulating MLL-AF9 
recruitment but may through interacting with other cofactors, such as the histone 
acetyltransferase TIP60, whose enzymatic activity could potentially facilitate 
gene transcription. Furthermore, although CBX8 is essential for MLL-AF9 
transformation, it is not required for normal hematopoiesis, as shown by the 
 xv 
 
normal viability of hematopoiesis in Cbx8-deficient mice. This suggests targeting 
CBX8 may be of therapeutic value in treating MLL-rearranged leukemias. In 
conclusion, our findings demonstrate that both PAFc and CBX8 play essential 




The Role of the PAF Complex in MLL Fusion Protein-Induced 
Leukemogenesis 
Introduction 
Mixed Lineage Leukemia 
Mixed lineage leukemia is a highly aggressive hematopoietic malignancy that 
occurs predominantly in pediatric patients. In contrast to other types of acute 
leukemia, mixed lineage leukemia stands out as a particular clinical challenge 
because patients with this disease present with an extremely dismal prognosis, in 
part due to their poor responses to conventional therapeutic treatment, such as 
chemotherapy (Balgobind et al., 2011; Slany, 2009). Mixed lineage leukemia 
possesses unique clinical features, which were first described in the early 1980s. 
At the time, physicians realized that certain subsets of patients initially diagnosed 
with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) fared 
far worse than others, especially some newborn and infant patients with similar 
clinical aspects. By fluorescent activated cell sorting (FACS) analysis, it was 
found that the leukemic blasts from these specific cases often expressed surface 
markers of both the myeloid and lymphoid lineages, although the 
immunophenotype may be more consistent with one or the other in a particular 
case (Krivtsov and Armstrong, 2007; Slany, 2009). In addition, a complete 
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lineage switch was even observed during treatment, meaning an ALL case could 
relapse as AML, therefore delivering the term of mixed lineage leukemia (Stass 
et al., 1984).  
Although chromosomal translocations causing the rearrangements of the 11q23 
locus were recognized as typical characteristics of mixed lineage leukemia soon 
after these genetic lesions had been observed, it was not until the early 1990s 
that the gene spanning this region was successfully cloned by four individual 
groups, which is now known as the mixed lineage leukemia (MLL) gene (Djabali 
et al., 1992; Gu et al., 1992; Tkachuk et al., 1992; Ziemin-van der Poel et al., 
1991). MLL rearrangements generate a large variety of oncogenic MLL fusion 
proteins. To date, more than 60 different fusion partners have been identified, 
among which the most common ones are nuclear proteins with transcriptional 
activating activity (Krivtsov and Armstrong, 2007; Monroe et al., 2010; Yokoyama 
et al., 2010). In ALL, the most common translocations are t(11;19) and t(4;11), 
resulting in the fusion proteins MLL-ENL and MLL-AF4, respectively. In contrast, 
the t(9;11) translocation, resulting in the MLL-AF9 fusion protein, is more 
frequently found in AML. In addition to the nuclear translocation partners, another 
class of MLL fusion partners consists of cytoplasmic proteins that contain 
dimerization domains, such as AF6. Dimerization of these MLL fusion proteins 
leads to potent transcriptional activation and is essential for their leukemogenic 
capacity; however, the detailed leukemogenic mechanism remains elusive 
(Martin et al., 2003; So et al., 2003). MLL-related translocations are also 
commonly observed in secondary acute leukemias after topoisomerase inhibitor 
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treatment (Felix, 1998). In addition, around 8% of AML patients with normal 
cytogenetic features harbor internal tandem duplications of partial MLL N-
terminal sequence, known as MLL-PTD (Figure 1.1). Overall, genetic lesions in 
the MLL gene are associated with more than 70% of infant leukemias and 
approximately 10% adult leukemias (Krivtsov and Armstrong, 2007). 
Wild-Type MLL  
The MLL gene encodes a histone methyltransferase containing a C-terminal SET 
domain that catalyzes the methylation of histone H3 lysine 4 (H3K4), a histone 
modification commonly associated with gene activation (Milne et al., 2002; 
Nakamura et al., 2002; Strahl et al., 1999). MLL was found to be part of a large 
chromatin-modifying complex that promotes transcription activation through 
histone methyltransferase and histone acetyltransferase activities (Nakamura et 
al., 2002). During the formation of this macromolecular complex, the MLL protein 
is cleaved by an aspartic protease named taspase into an N-terminal fragment 
(MLLN) and a C-terminal subunit (MLLC) (Hsieh et al., 2003a; Hsieh et al., 2003b; 
Takeda et al., 2006; Yokoyama et al., 2002). On the one hand, the MLLN 
fragment contains several functional regions that are considered essential for 
correct localization of the MLL complex. On the other hand, the MLLC subunit 
associates with at least four proteins, including MOF, WDR5, ASH2L and RBBP5, 
to modify chromatin structure, thereby facilitating transcription activation. Among 
these critical interacting partners, MOF neutralizes charges on histones by 
depositing a site-specific acetylation mark on histone H4 lysine 16, potentially 
decondensing chromatin for efficient transcription (Slany, 2009). WDR5, ASH2L 
 4 
 
and RBBP5 form a common structural platform, which stabilizes the functionally 
active configuration of the catalytic MLLC fragment. In particular, WDR5 mediates 
MLLC interactions both with this platform and with the histone substrate, which in 
turn achieves the full H3K4 methyltransferase activity of the MLL complex (Dou 
et al., 2006; Ruthenburg et al., 2006; Schuetz et al., 2006; Southall et al., 2009). 
In summary, the MLLN and MLLC fragments, in coordination with the other MLL 
complex components, modulate the chromatin structure at MLL target loci, 
thereby mediating transcriptional regulation of downstream genes.  
Major MLL Targets – HOX Genes 
Based on the sequence similarity, MLL is a human homolog of the Drosophila 
trithorax (TrxG) protein originally identified in genetic screens as “anti-silencers” 
counteracting the action of Polycomb group (PcG) proteins that represses Hox 
gene expression (Mills, 2010). Consistent with the role of Drosophila TrxG 
proteins, in mice, Mll is required for normal embryonic development through 
maintaining the proper Hox gene expression pattern (Yu et al., 1995).  Several 
studies demonstrated that it also plays a central role in regulating hematopoietic 
stem cell self-renewal and progenitor expansion (Jude et al., 2007; McMahon et 
al., 2007). Notably, Hox gene expression is dynamically regulated and 
functionally important in these processes (He et al., 2011).  
Hox genes encode a large family of transcription factors that are evolutionarily 
conserved among metazoans. They play crucial roles during development by 
regulating a number of important physiological processes, including apoptosis, 
receptor signaling, cell motility, angiogenesis and hematopoiesis (Shah and 
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Sukumar, 2010). In human, a total of 39 HOX genes have been identified. They 
are linked in as four separate clusters, HOXA, HOXB, HOXC and HOXD, located 
on chromosomes 7, 17, 12 and 2, respectively (Ansari and Mandal, 2010). Based 
on sequence similarities and their positions within the clusters, they are further 
classified into 13 paralogue groups arranging from position 1 to 13 in a 3’-5’ 
direction (He et al., 2011; Krumlauf, 1994).  
This clustered organization is of particular interest because it correlates with the 
temporal and spatial expression patterns of Hox genes, meaning that the 3’ Hox 
genes are expressed first and are more restricted to the anterior region of the 
embryo, whereas the 5’ Hox genes are expressed sequentially later and more 
caudally (He et al., 2011). Mutation of single Hox genes does not cause dramatic 
alterations in morphogenesis in vertebrates, suggesting functional redundancy 
within the Hox family. Nevertheless, the expression of specific Hox genes and 
combinations of Hox gene products vary at different stages of development, 
indicating that proper regulation and maintenance of Hox gene expression are 
essential mechanisms governing developmental processes. For instance, Hox1-6 
genes are maximally expressed in hematopoietic stem cells, whereas Hox7-13 
genes are present in committed progenitors. During definitive hematopoiesis, 
Hox gene expression decreases as differentiation proceeds. In particular, 
previous studies have shown that 3’ HoxA and HoxB cluster genes are 
preferentially expressed in primitive hematopoietic stem cells (HSCs), relative to 
their levels in the HSC-low or HSC-depleted subpopulations (Guo et al., 2003; 
Pineault et al., 2002). Moreover, in hematopoietic cells, Hox genes are 
 6 
 
expressed in a lineage-specific manner, with most HoxB and certain HoxC genes 
selectively expressed in cell lines showing erythroid characteristics and certain 
HoxA genes predominantly expressed in myeloid-lineage cell lines (Lawrence et 
al., 1996). More specifically, populations enriched for myeloid progenitors 
preferentially express 5’ Hox genes, such as HoxA9, HoxB9 and HoxA10, and 
these genes are coordinately activated in myeloid leukemia cells (Celetti et al., 
1993). 
Leukemogenic MLL Fusion Proteins 
The most striking property of leukemogenic MLL fusion proteins is the significant 
diversity of this family. While the oncogenic mechanisms are likely to differ in 
detail, all rearranged forms of MLL upregulate expression of certain HOX genes 
and their cofactors, including HOXA9 and MEIS1, which is critical for 
leukemogenic transformation (Armstrong et al., 2002; Ayton and Cleary, 2003; 
Kumar et al., 2004). Although it is well established that constitutive activation of 
these downstream targets, particularly HOXA9, is a key feature of MLL leukemia 
pathogenesis, the molecular mechanisms governing the aberrant HOX gene 
activation have not been defined (Sitwala et al., 2008; Yokoyama and Cleary, 
2008).  
Within multiple domains that are present in the wild-type MLL protein, only the N-
terminus containing the Menin interaction domain, AT-hooks and CxxC-RD2 
domain (up to the break point region) are invariably retained in all MLL-
rearranged oncoproteins, whereas the Plant Homeodomain (PHD) and the SET 
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domain, which is required for the histone methyltransferase activity, are 




Figure 1.1 Schematic of Wild-Type MLL and MLL-Rearranged Oncoproteins. Major 
functional domains and the proteolytic cleavage site of wild-type MLL are indicated. MLL 
fusion proteins consist of the N-terminus of wild-type MLL (up to the breakpoint region) 
fused in frame with a translocation partner (either a nuclear protein, such as ENL, AF4 
and AF9, or a cytoplasmic protein, such as AF6). MLL-PTD is generated by exon 





been conducted to explore the functional significance of the retained portion of 
MLL in MLL fusion proteins in transcriptional activation and leukemogenesis. For 
example, Menin, a tumor suppressor encoded by the MEN1 gene, directly 
interacts with the extreme N-terminus of MLL, and this interaction is essential for 
MLL-rearranged leukemogenesis (Caslini et al., 2007; Chen et al., 2006). This 
interaction also involves a chromatin-associated protein, LEDGF (lens 
epithelium-derived growth factor) (Yokoyama and Cleary, 2008). Moreover, the 
CxxC domain selectively binds unmethylated CpG DNA and contributes to the 
binding of MLL fusion proteins to the target loci, protecting the corresponding 
regions against DNA methylation (Ayton et al., 2004). However, the role of the 
CxxC-RD2 region, particularly the RD2 region that is immediately adjacent to the 
CxxC domain and proceeds to the breakpoint region, in the cellular activities of 
wild-type MLL or MLL fusion proteins remains elusive. The importance of this 
region is highlighted by recent work by Bach et al. who demonstrated that the 
DNA-binding affinity alone does not fully account for the indispensible role of this 
region in leukemogenesis, indicating the presence of uncharacterized activities or 
interactions critical for MLL-rearranged leukemogenesis (Bach et al., 2009).  
On the other hand, during MLL rearrangements, the SET domain at the C-
terminus of wild-type MLL is replaced by translocation partners. The mechanisms, 
by which the major fusion partners contribute to MLL-rearranged leukemogenesis, 
are beginning to be defined (Monroe et al., 2010). It has been reported that a 
complex of proteins termed ENL-associated proteins (EAPs), or a closely related 
complex named AEP for AF4 family/ENL family/P-TEFb complex, interacts with 
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the major MLL fusion partners AF9, ENL and AF4 (Lin et al., 2010; Muntean et 
al., 2010; Yokoyama et al., 2010). The EAP complex includes both the common 
MLL fusion partners, such as AF9 and ENL, and also the histone 
methyltransferase DOT1L and the P-TEFb complex (consisting of CDK9 and 
cyclin T1), both of which positively regulate transcription elongation (Krivtsov et 
al., 2008; Mueller et al., 2007). Meanwhile, other investigators have described an 
H3K79 methyltransferase complex, DotCom, which contains several common 
MLL fusion partners, including AF9, ENL and AF10, that play a positive role in 
leukemogenesis (Mohan et al., 2010a). The components of these complexes 
partially overlap, suggesting that they may share certain mechanisms that 
contribute to MLL-rearranged leukemogenesis (Mohan et al., 2010b; Mueller et 
al., 2007). Notably, the interaction partners of MLL fusion proteins are distinctive 
from the components of the wild-type MLL complex, suggesting that they may 
activate transcription through differential mechanisms.  
PAFc 
The Polymerase Associated Factor complex (PAFc) is a multi-protein complex, 
with the core components of PAF1, LEO1, CDC73, CTR9, WDR61 (also known 
as hSki8), and, in some cases, Rtf1 (Jaehning, 2010a; Kim et al., 2010; 
Rozenblatt-Rosen et al., 2005; Zhu et al., 2005a). Increasing evidence has 
revealed that PAFc plays important roles in a wide range of biological processes, 
including H2B monoubiquitination, the initiation, elongation and termination of 
gene transcription, cell cycle regulation, and mRNA processing (Figure 1.2) 
(Chaudhary et al., 2007; Kim et al., 2009; Kim and Roeder, 2009).  
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In addition, several components of PAFc are known to play important roles in 
carcinogenesis. For instance, in a study to identify genes involved in pancreatic 
tumor progression, PAF1 was found to be overexpressed as a result of a double 
minute amplification involving chromosome 19q13 (Batra et al., 1991). Along this 
line, overexpression of PAF1 results in transformation of NIH3T3 cells (Moniaux 
et al., 2006). These findings suggest that PAF1 may function as an oncogene 
promoting tumorigenesis. In contrast, CDC73 has been implicated to serve as 
both a tumor suppressor and an “aider and abettor” of an oncoprotein in a 
context-dependent manner. One the one hand, most notably mutations in CDC73, 
encoded by HRPT-2 (hereditary hyperparathyroidism type 2), are responsible for 
the familial hyperparathyroidism-jaw tumor (HPT-JT) syndrome (Szabo et al., 
1995). HPT-JT is an autosomal dominant disorder associated with 
hyperparathyroidism (HPT) and a high incidence of parathyroid adenomas, 
hyperplasias and carcinomas as well as renal abnormalities and uterine tumors 
(Newey et al., 2009). Some mutations in HRPT-2 are predicted to lead to loss of 
function due to premature termination. The chromosome 1q25-q31 region 
spanning HRPT-2 frequently undergoes loss of heterozygosity in tumors arising 
in HPT-JT patients, suggesting that CDC73 functions as a tumor suppressor 
(Newey et al., 2009). Consistent with this role, overexpression of wild-type 
CDC73, but not a mutant form found in HPT, blocks cell proliferation and inhibits 
the cell cycle regulator cyclin D1 (Woodard et al., 2005). On the other hand, 
CDC73 overexpression in 293T and COS7 cells increases S-phase entry and 
promotes cellular proliferation. This induction of CDC73-mediated cell-dependent 
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proliferation requires the SV40 large T-antigen, which is directly bound by 
CDC73 (Iwata et al., 2007), suggesting the potential role of CDC73 as an 
oncogene cofactor. In addition, the CTR9 gene has been localized to 
chromosome 11p15, which contains chromosomal aberrations associated with 
the pathogenesis of different tumor types including lung cancer and leukemia 




Figure 1.2 Overview of Paf1C Interactions with Transcriptional Activation, Histone 





Previous studies have demonstrated that the yeast PAF complex is required for 
the recruitment of the yeast Set1 methyltransferase complex, termed COMPASS, 
to RNA polymerase II. It is also indispensable for both COMPASS-mediated 
histone H3K4 and Dot1L-mediated H3K79 methylation (Krogan et al., 2003; 
Rozenblatt-Rosen et al., 2005). Given that the MLL complex is a human homolog 
of COMPASS, and that the only H3K79 methyltransferase in human, hDOT1L, is 
recruited by MLL fusion proteins, it is both mechanistically important and 
therapeutically intriguing to investigate whether PAFc is physically and 
functionally associated with the MLL complex, as well as the leukemogenic MLL 
fusion protein complexes. 






Materials and Methods 
Cell Culture 
293 and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10%FBS and 1X non-essential amino acids. MLL-
ENL and E2A-HLF cells were cultured in Iscove's modified Dulbecco's medium 
(IMDM) supplemented with 15% fetal calf serum (FBS) (Stem Cell Technologies). 
Hoxa9-ER cells were cultured in IMDM supplemented with 15% FBS and 0.1% 
IL3. Plat-E cells were cultured in DMEM supplemented with 10% FBS. HL-60, 
THP-1, KOPN8 and K562 cells were cultured in RPMI-1640 medium 
supplemented with 10% FBS. Differentiation of HL-60 and THP-1 cells was 
induced by 10 nM PMA treatment.  
Luciferase Assay 
293 cells were transiently transfected with MSCV MLL-AF9 (and derivatives), 
CMV-Renilla, and Hoxa9-LUC (or Myc-E box-LUC) constructs using FuGene 6 
(Roche) according to manufacturer’s instructions. Cells were then serum starved 
in 0.5% FBS in OPTI-MEM media for 48 hours. Luciferase assays were 
performed using the Dual Luciferase assay kit (Promega) according to 
manufacturer’s instructions. Emission was detected using a Monolight 3010 (BD 
Biosciences). 
Vector Construction 
The pFMLL-AF9 vector and pMSCV-neo constructs encoding MLL-AF9 have 
been described previously (Muntean et al., 2008). The expression vectors for 
various MLL-AF9 deletions and CxxC-RD2-AF9 deletions tagged with FLAG/Myc 
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were generated by restriction enzyme digestion and PCR-based mutagenesis. 
Expression vectors for CDC73, CTR9, PAF1, LEO1 and WDR61 were purchased 
from Origene. pSM2c scrambled, pSM2c shCdc73 (clone ID V2MM_49292) and 
pSM2c shCtr9 (clone ID V2MM_46348) retroviral vectors were purchased from 
Open Biosystems. 
Retrovirus Packaging 
pMSCV (for FLAG-MLL-AF9 and deletions) and pSM2c (for shScram, shCdc73 
and shCtr9) were transfected using FuGene 6 reagent (Roche) into Plat-E cells 
and selected using puromycin (1 µg/ml) and blasticidin (10 µg/ml). Media 
containing the recombinant retrovirus was collected for transduction at 48 and 72 
hours post transfection.   
Bone Marrow transformation assays 
Bone marrow transformation assays were performed as described (Muntean et 
al., 2008) with the addition of p-iodonitro tetrazolium violet (INT) staining of 
tertiary colonies. Briefly, bone marrow was isolated from 6-8 week old C57B6 
mice injected with 5-fluorouracil. Cells were collected from the tibia and femur 
and cultured in pre-stimulation cocktail that includes SCF, IL3 and IL6. Cells were 
transduced by spinoculation twice with MLL-AF9 or MLL-AF9 deletion 
retroviruses and plated in MethoCult® M3234 (Stem Cell Technologies) with IL3, 
IL6, SCF, GM-CSF and 1mg/ml G418. After three rounds of replating colonies 
were stained with 0.1% INT for 30 minutes and scored. Cells harvested from 
bone marrow transformation assays were cytospun and stained with Hema 3 
Stain Kit (Thermo Fisher Scientific). Images were acquired using a 100× lens and 
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Olympus BX-51 microscope with Olympus DP controller software (Olympus). For 
knock down experiments, MLL-AF9 transduced cells were collected after the 
second round of plating and transduced twice with either scrambled control 
retrovirus, shCdc73 retrovirus or shCtr9 retrovirus by spinoculation and replated 
in the MethoCult® medium described above and selected in 2 µg/ml puromycin 
at 5 x 104 cells per plate. Colonies of greater than 50 cells were scored after the 
final replating. All animal studies were approved by the University of Michigan 
Committee on Use and Care of Animals and Unit for Laboratory Medicine. 
Immunoprecipitation and Immunoblotting 
Preparation of cell lysates, immunoprecipitation, and immunoblotting were 
performed as described previously (Muntean et al., 2008). 293 cells were 
transiently transfected with FuGene 6 (Roche) according to manufacturer’s 
instructions. Cells were lysed in BC-300 buffer (20mM Tris-HCl (pH 7.4), 10% 
glycerol, 300 mM KCl, 0.1% NP-40), and immunoprecipitations were performed 
overnight with resins described below. IPs were washed 4 times with BC-300 
buffer and proteins were eluted by boiling in SDS-loading buffer. Proteins were 
visualized by SDS-PAGE and western blotting. Primary antibodies included 
rabbit anti-Paf1, anti-Leo1, anti-Parafibromin, anti-Ctr9 (Bethyl Laboratories, Inc.) 
and mouse anti-WDR61 (Abcam). Rabbit anti-MLL C was generously provided 
by Dr. Yali Dou. Additional primary antibodies included rabbit anti-Hoxa9 
(Millipore), goat anti-Myc (Abcam), mouse anti-beta-actin (Sigma), rabbit anti-
cyclin-T1 (H-245) (Santa Cruz) and rabbit anti-HA tag (Abcam). Rabbit anti-FLAG 
antibody and agarose affinity beads coupled to mouse anti-FLAG M2 monoclonal 
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antibody were purchased from Sigma. Agarose affinity beads coupled to mouse 
anti-Myc monoclonal antibody were purchased from Clontech. 
In Vitro Binding 
Equal amounts of MLL and individual PAF proteins (1-2 µg) along with 15 µl of 
Protein G affinity agarose beads (Roche) were incubated with MLL antibodies 
(Bethyl) in Binding Buffer (50 mM Tris-HCl pH7.9, 100 mM KCl, 0.05% NP40, 
0.1% BSA) overnight at 4 degrees. Bound material was washed with Wash 
Buffer (50 mM Tris-HCl pH 7.9, 500 mM KCl, 0.3% NP40) 4 times and eluted 
from beads by boiling in SDS loading buffer. Eluted material was visualized by 
western blot or Coomasie staining. Reciprocal IPs were performed by incubating 
individual PAF proteins and MLL fragments with Amylose resin (New England 
Biolabs) in Binding Buffer overnight at 4 ℃. Bound material was washed with 
Wash Buffer 4 times and eluted by boiling in SDS loading buffer. Proteins were 
visualized as described above.  
Protein Identification by LC-Tandem Mass Spectroscopy 
293 cells were transiently transfected with control or FLAG/HA CxxC-RD2 
vectors as described above. Cells were lysed and immunoprecipitations were 
performed as described above. Bound material was eluted with 40 µg FLAG 
peptide followed by 15 rocking at 4 ℃ (Sigma). FLAG elutions were repeated and 
protein was concentrated with a Micron YM-30 centrifugal filter column (Millipore). 
Proteins were separated by SDS-PAGE on a 4-20% gradient tris-glycine gel and 
visualized by silver staining (Sigma). Silver stained (PROTSIL-2, Sigma) gel 
lanes corresponding to control and CxxC-RD2 IP were cut into 16 slices each 
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and destained following manufacturer’s protocol.  Upon reduction (10 mM DTT) 
and alkylation (50 mM iodoacetamide) of the cysteines, proteins were digested 
overnight with sequencing grade, modified trypsin (Promega).  Resulting 
peptides were resolved on a nano-capillary reverse phase column (Picofrit 
column, New Objective) using a 1% acetic acid/acetonitrile gradient at 300 nl/min 
and directly introduced in to an ion-trap mass spectrometer (LTQ XL, 
ThermoFisher).  Data-dependent MS/MS spectra on the 5 most intense ion from 
each full MS scan were collected (relative CE ~35%).  Proteins were identified by 
searching the data against Human IPI database (v 3.41, 72,254 entries) 
appended with decoy (reverse) sequences using X!Tandem/Trans-Proteomic 
Pipeline (TPP) software suite (Keller et al., 2002) (Nesvizhskii et al., 2003).  All 
proteins with a ProteinProphet probability score of >0.9 (error rate <2%) were 
considered positive identifications and manually verified. 
Bacterial Expression 
CxxC-RD2, RD2, PAF1 and LEO1 were cloned into the pMocr (DelProposto et 
al., 2009) bacterial expression vector, which contains a His-MOCR tag. CDC73, 
CTR9-N and CTR9-C were generated by cloning into the pMCSG9 (Donnelly et 
al., 2006) vector with a His-MBP tag. Expression plasmids were transformed into 
BL21(DE3) bacteria containing pRARE-CDF (for additional tRNA expression) 
and screened at the University of Michigan High-Throughput Protein Lab. 
Bacteria was grown at 37 degrees Celsius in TB at 250 rpms with 50ug/ml 
spectinomycin and 100 µg/ml ampicillin to an OD600 of approximately 1 followed 
by temperature reduction to 20 degrees Celsius for 1 hour. Protein expression 
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was induced with 200 µM IPTG and continued growth overnight. Proteins were 
purified by lysis in CelLytic B buffer (Sigma) supplemented with 0.15 M NaCl, 1 
mM PMSF, 1 mM DTT, 0.4 mg/ml lysozyme, 2 mM MgCl2, and 100 units/ml 
Benzonase. Proteins were purified over a Ni column (GE Pharmacia) using an 
AKTA Purifier liquid chromatography system (GE Pharmacia) and eluted with 20 
CV of elution buffer (20 mM Tris-HCl, pH 7.5, 10% glycerol, 1 mM DTT, 0.15 M 
NaCl, 20-500 mM imidazole). Secondary purifications were performed using a 
Mono-Q column (GE Pharmacia) or amylose column (GE Pharmacia) and 
identical elution buffers except 0.15 M-1 M NaCl gradient. Purified proteins were 
visualized by Coomasie staining.   
Real Time PCR 
RNA was extracted from cells using TRIzol reagent (Invitrogen). cDNA was 
generated using Superscript III Reverse Transcriptase (Invitrogen) according to 
manufacturer’s instructions. Relative quantitation of real time PCR product was 
performed using comparative ΔΔCt method (described in ABI Prism 7700 
Sequence Detection System User Bulletin No. 2) and TaqMan or SYBR green 
fluorescent labeling and ABI 7500 PCR Detection System. FLAG-MLL-AF9 was 
detected using the following primers for SYBR green detection: FLAG-F-5’-
ggactacaaggacgacgatga-3’ and MLL-R-5’-acagctgtgcgccatgtt-3’. TaqMan primer 
probe sets were purchased from Applied Biosystems for mouse Hoxa9, Meis1, 
Paf1, Leo1, Cdc73, Ctr9, Wdr61, and human PAF1, LEO1, CDC73, CTR9, 
WDR61 and HOXA9.   
THP-1 Electroporation and FACS 
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THP-1 cells were transfected with pTurbo-GFP and either empty MSCV or a 
mixture of the five PAFc expression plasmids at a ratio of 1:5. A total of 600 ng of 
DNA was transfected into THP-1 cells using the Amaxa Nucleofector II device 
(Lonza) using Amaxa Cell Line Nucleofector Kit V for THP-1 cells according to 
manufacturer’s instructions. Briefly, 1X106 cells were transfected using either 
program U-001 or V-001. Cells were allowed to recover overnight. Cells were 
split in half with one half being treated with 10 nM PMA to induce differentiation. 
Cells were incubated an additional 24 hours and then washed twice with PBS 
followed by staining with PE-mouse anti-human CD11b or isotype control (BD 
Pharmingen). After 30-minute incubation cells were washed with Standard Buffer 
(1X PBS, 0.1% sodium azide, 1% heat inactivated FBS) twice and resuspended 
in 250 µl Standard Buffer. FACS data was collected on an LSRII (BD). CD11b 
expression was monitored on both the GFP positive and GFP negative 
populations as an internal control. 
Chromatin Immunoprecipitation 
ChIP was performed as described previously (Milne et al., 2005a) using primary 
antibodies specific for MLLC (gift from Dr. Yali Dou), ENL (gift from Dr. Robert 
Slany), histone H3, H3K4 dimethylation, H3K4 trimethylation and H3K79 tri-
methylation (Abcam) and Paf1, Leo1, Parafibromin and Ctr9 (Bethyl Laboratories 
Inc,. as described above). Quantitative real-time PCR was performed on the 
precipitated DNAs with TaqMan fluorescent labeling using the following primers 
and qPCR probes:  




Forward Primer – TCTAACCTTTCCAAGTCCTCGTAAA 
Reverse Primer – GCGGGAAGTCGGAAACG 
Probe – FAM-CCACGGCGAGGCAAACGAATCT-TAMRA 
Coding 
Forward Primer – GGCCCAGGACCGAGATACTT 
Reverse Primer – CGCTCACGGACAATCTAGTTGT 
Probe – FAM-CGTTCTTCGAAAGCAGTGCAGCCC-TAMRA 
Mouse Hoxa9 TaqMan primer probe sets have been described earlier (Milne et 
al., 2005a). 
Binding was quantitated as follows: ΔCT = CT(input) - CT(Chromatin IP), % total = 
2ΔCT. 
siRNA Knockdown of PAFc 
siRNA smart pools were obtained from Dharmacon for CTR9, CDC73, PAF1 and 
LEO1. siRNA transfection of HeLa cells was achieved using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions for analysis in luciferase 
assays. Oligofectamine (Invitrogen) was used according to manufacturer’s 
instructions for siRNA transfection of HeLa cells and PAFc knock down for ChIP 
assays. 
Accession Numbers 
Microarray data has been deposited in the Gene Expression Omnibus (GEO) 
repository from the National Center for Biotechnology Information (NCBI) with 




PAFc Interacts with the CxxC-RD2 Domain of MLL 
To identify proteins that associate with MLL CxxC-RD2, we transiently expressed 
epitope tagged portions of this region in human embryonic kidney 293 cells 
(Figure 1.3A). FLAG-tagged CxxC-RD2 including a nuclear localization signal 
(NLS) was immunoprecipitated from transiently transfected 293 cells using M2 
anti-FLAG agarose beads.  An “empty” expression vector with FLAG epitope tag 
and NLS was also subjected to immunoprecipitation as a non-specific 
immunoprecipitation control. Coeluted proteins were resolved by SDS-PAGE 
(Figure 1.3B) and analyzed by mass spectroscopy. Multiple peptides 
corresponding to subunits of PAFc were identified with high probability including 
CTR9, LEO1, PAF1, CDC73 and WDR61 that correlated with silver stained 
bands at 133 kDa, 105 kDa, 75 kDa, 64 kDa and 34 kDa, respectively (Figures 
1.3B and 1.3C). Each of the five PAFc subunits identified by mass spectrometry 
(PAF1, CDC73, CTR9, LEO1 and WDR61) was confirmed to co-
immunoprecipitate with Myc-tagged CxxC-RD2 by western blotting in 293 cells 






Figure 1.3 MLL Fragment Interacts with the PAF Complex (PAFc) (A) Schematic 
diagram of the full-length MLL protein with key domains indicated. The FLAG/HA tagged 
CxxC-RD2 MLL fragment used for immunoprecipitation is shown below. The first and 
last amino acids of the protein fragments are indicated. (B) MigR1 and FLAG/HA-tagged 
CxxC-RD2 was expressed in 293 cells and immunoprecipitated. Immunoprecipitates 
were analyzed by SDS-PAGE and visualized by silver staining. Arrows indicate bands at 
the predicted molecular weights of the PAF complex components. (C) PAFc 





To exclude the possibility of a DNA-mediated MLL-PAFc interaction and confirm 
that the PAFc interaction is preserved in the context of a fusion protein, 
immunoprecipitations were repeated with Myc-tagged CxxC-RD2-AF9 in 293 
cells following Benzonase treatment. Immunoprecipitation was preserved in the 
presence of Benzonase suggesting the interaction is not DNA dependent (Figure 
1.4B). Furthermore, PAFc co-immunoprecipitated with Myc-CxxC-RD2-AF9, as 
well as with CxxC-RD2 (Figures 1.4B-1.4D).  
These experiments were repeated with transfection of an expression vector for 
FLAG-tagged full-length MLL-AF9 or wild-type MLL into 293 cells followed by 
immunoprecipitation and western blotting (Figures 1.5A and 1.5B). We also 
confirmed the PAFc interaction by co-immunoprecipitation of CDC73 with MLL-
ENL in the KOPN8 cell line (Figure 1.5C). Together, these experiments show the 
MLL-PAFc interaction is maintained both in the context of full-length (MLLN) and 






Figure 1.4 MLL and MLL-AF9 Fragments Interact with PAFc in a DNA-Independent 
Manner (A) Immunoprecipitation and western blot of the PAF complex following 
immunoprecipitation of Myc tagged CxxC-RD2 or Myc tag control. (B) The experiment 
described in A was repeated in the presence of Benzonase, using CxxC-RD2-AF9 
fragment. Myc tagged CxxC-RD2-AF9 but not the Myc tag alone interacts with PAFc 
subunits. (C) Immunoprecipitation of Myc tagged CxxC-RD2 and western blot showing 
interaction with the PAF components CTR9 and PAF1 in the presence of Benzonase. (D) 
Lysates from the experiment shown in B and C were treated with Benzonase. Ethidium 
bromide staining of an agarose gel before and after Benzonase treatment shows 






Figure 1.5 MLL and MLL Fusion Proteins Interact with PAFc in a DNA-Independent 
Manner (A and B) A full-length FLAG-tagged MLL-AF9 fusion protein (A) or wild-type 
MLL (B) was expressed in 293 cells and immunoprecipitated. PAFc stably associated 
with full-length MLL-AF9 and wild-type MLL as indicated by western blot. (C) 
Immunoprecipitation of endogenous MLL-ENL from KOPN8 cells and western blotting 
for the PAF component CDC73 shows interaction of endogenous MLL-ENL with 
endogenous PAFc. IP of wild-type ENL in K562 cells serves as a negative control.   
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To determine if the interaction between MLL and PAFc is direct and to identify 
the PAFc subunit(s) involved, we bacterially expressed and purified the MLL 
CxxC-RD2 region (amino acids 1115 - 1396) and the RD2 region alone (amino 
acids 1202 - 1396) for in vitro pull-down experiments with bacterially expressed 
PAF1, LEO1, CDC73 and CTR9 (expressed as N and C terminus proteins 





Figure 1.6 Schematic Diagram of MLL and Bacterially Purified CxxC-RD2 and RD2 
Regions. Starting and ending amino acids are indicated.  
 
were performed with either CxxC-RD2 or RD2 with MLL antibodies after 
incubation with individual components of PAFc. Strong interaction of PAF1 with 
CxxC-RD2 but not the RD2 region was detected indicating an interaction 
between PAF1 and amino acids 1115 and 1201 of MLL (Figure 1.7). These 
findings are consistent with our in vivo immunoprecipitation experiments in which 
PAFc co-immunoprecipitated with a small fragment of MLL N-terminal to the 
CxxC domain (amino acids 1115 - 1154) (Figure 1.8, see below). We also 
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detected a second interaction between CTR9-C and both the MLL CxxC-RD2 




Figure 1.7 PAF1 and CTR9 Bind Directly to the CxxC-RD2 Region of MLL (A) 
Coomassie blue staining of bacterially purified His-MOCR tagged CxxC-RD2, RD2, 
PAF1, LEO1, and His-MBP tagged CDC73, CTR9-N and CTR9-C. The amino acids of 
CTR9-N and CTR9-C are indicated. (C) Immunoprecipitations performed with bacterially 
purified recombinant CxxC-RD2 or RD2 and PAF complex components. Individual PAF 
components were incubated with either CxxC-RD2 or RD2 and immunoprecipitated with 
MLL antibodies. PAF components and immunoprecipitated MLL fragments were 
detected with the indicated antibodies by western blot. Asterisk denotes detection of the 
IgG heavy chain.   
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We then performed a series of deletion experiments to further map the MLL 
residues that participate in the MLL-PAFc interaction. Expression vectors for 
Myc-tagged CxxC-RD2-AF9 deletion mutants spanning the RD2 region of MLL 
(Figure 1.8A, Cx-1154-AF9 through Cx-1357-AF9) were transiently transfected 
into 293 cells and tested for PAFc interaction. These experiments reveal a sharp 
decrease in the MLL-PAFc interaction when C terminal deletions were made past 
amino acid 1299 (Figure 1.8B, compare lanes 6 and 7). To overcome the 
residual low level binding of PAFc with proteins deleted at amino acids 1209 or 
amino acids 1258, presumably due to the multiple binding sites between PAFc 
and MLL, which were only partially affected by these deletions (Figure 1.7), we 
repeated this experiment with a set of deletion constructs that begin with MLL 
amino acid 1180 thereby deleting the proximal site of PAFc interaction (Figure 
1.9A, Cx-del-1209-AF9 through Cx-del-1357-AF9). These experiments showed 
PAFc interaction with MLL is completely eliminated with deletions beyond amino 
acid 1299 (Figure 1.9B, compare lanes 4 and 5). Together, our data suggest the 
MLL-PAFc interaction is multivalent involving residues of MLL in both the pre-
CxxC domain and the RD2 region. Furthermore, the binding of PAFc by both pre 
and post CxxC domains is consistent with the structure of the MLL CxxC domain 
determined by multidimensional NMR spectroscopy (Protein Database structure, 
2J2S) (Allen et al., 2006), which shows the DNA binding CxxC domain 
coordinates two zinc atoms thereby bringing the pre and post CxxC regions into 






Figure 1.8 Amino Acids within the RD2 Region are Necessary for MLL-PAFc 
Interaction (A) Schematic of Myc-tagged CxxC-RD2-AF9 constructs made with serial 
deletions of the RD2 region. The first and last MLL amino acid retained in the expression 
constructs are indicated. All constructs include the AF9 fusion partner at the C-terminus 
and Myc tag at the N-terminus. The Cx-1154-AF9 through Cx-1357-AF9 constructs are 
named according to the last MLL residue retained in the fusion protein. (B) Myc-tagged 
RD2 deletion constructs described in A were expressed in 293 cells followed by 
immunoprecipitation. The Myc-tagged MLL deletion proteins and associated PAF 





Figure 1.9 Pre-CxxC and RD2 Regions are Both Involved in MLL-PAFc Interaction 
(A) Schematic of a second set of deletion constructs made through the RD2 region that 
also delete the pre-CxxC domain. Cx-del-1209-AF9 through Cx-del-1357-AF9 were 
made by deleting amino acids 1115 through 1179 of MLL. The amino acids included in 
each construct are indicated. (B) Myc tagged constructs described in C were expressed 




PAFc Stimulates Transcriptional Activation Induced by MLL and MLL 
Fusion Proteins 
We then tested whether PAFc affects the transcriptional output mediated by MLL 
and the MLL-AF9 fusion protein. Dual luciferase assays were performed in 293 
cells transfected with a luciferase reporter construct under the transcriptional 
control of the murine Hoxa9 promoter (Hoxa9-LUC). These experiments showed 
that transcriptional activation by wild type MLL is enhanced by co-expression of 
the five PAFc subunits (Figure 1.10A). Consistent with our earlier finding (Milne 
et al., 2002), we observed a dose dependent transcriptional activation of the 
reporter gene driven by the Hoxa9 promoter by expression of increasing amounts 
of MLL-AF9 (Figure 1.10B). Furthermore, we observed a dose-dependent 
augmentation of MLL-AF9 dependent transcription when increasing amounts of 
PAFc were expressed. Notably, expression of PAFc alone had little effect in our 
assay (Figures 1.10A and 1.10B). A similar trend was observed when using an 
MLL-AF9 responsive luciferase construct containing a thymidine kinase promoter 
and multimerized Myc E-boxes (Figure 1.11). Furthermore, we did not observe 
augmented transcription when single PAF components were introduced (Figure 
1.10C). Together, these findings show that MLL and MLL-AF9 synergize with 





Figure 1.10 PAFc Synergizes with MLL and MLL-AF9 to Augment Transcriptional 
Activity (A) Luciferase assays were performed with the Hoxa9-LUC reporter construct 
and increasing doses of full length MLL (lanes 1-4) (0-0.6 µg) or PAFc (lanes 5-8) (0 – 
0.6 µg). PAFc includes equal amounts of PAF1, LEO1, CDC73, CTR9 and WDR61. 
Lanes 9-12 show constant MLL (0.6 µg) with increasing doses of PAFc (0-0.6 µg). All 
changes are shown relative to lane 1. Error bars indicate +/- SD. Results of one of three 
representative experiments performed are shown. (B) Experiment was performed as 
described in A, except for using MLL-AF9 instead of MLL. Error bars indicate +/- SD. 
One of three representative experiments is shown. (C) Luciferase assay performed in 
transfected 293 cells using the Hoxa9-LUC reporter construct and individual PAFc 
components in lanes 1-6, PAFc (lane 7), MLL-AF9 alone (lane 8), MLL-AF9 plus 
individual PAF components (lanes 9-13) and MLL-AF9 with PAFc (lane 14). Error bars 





Figure 1.11 PAFc Synergizes with MLL-AF9 to Promote Transcription (A) Luciferase 
assays were performed in transiently transfected 293 cells with a Myc-E-box-LUC 
reporter construct and increasing doses of MLL-AF9 (lanes 1-4) (0-0.6 µg). Increasing 
doses of PAFc were transfected in lanes 5-8 (0-0.6 µg). Increasing doses of PAFc (0 – 
0.6 µg) were transfected with constant MLL-AF9 (0.6 µg) in lanes 9-12. Error bars 
indicate the standard deviation of experiment performed in triplicate. One of more than 
three representative experiments is shown. B) Luciferase assays were performed as 
described in A except individual PAF components were transfected (lanes 1-6), PAFc 
(lanes 7), MLL-AF9 (lane 8), MLL-AF9 plus individual PAF components (lanes 9-13) and 
MLL-AF9 plus PAFc (lane 14). Error bars indicate the standard deviation of experiment 
performed in triplicate. One of three representative experiments is shown. 
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MLL Fusion Protein-Mediated Transformation Is Dependent upon 
Interaction with PAFc 
We then tested whether the transforming potential of MLL fusion proteins is 
dependent on the MLL-PAFc interaction. The deletions in the MLL RD2 region 
tested in immunoprecipitations described above (Figure 1.8A) or the pre-CxxC 
region were cloned into full-length MLL-AF9 in MSCV-based retroviral vectors 
(Figure 1.12B). These were packaged in Plat-E cells and transduced into 5-FU 
primed bone marrow and analyzed in methylcellulose replating assays as 
previously described (Morita et al., 2000). Briefly, transduced cells were cultured 
under G418 selection in the presence of IL3, IL6, GM-CSF and SCF and colonies 
quantitated after the first, second and third rounds of replating (Figure 1.12A). 
Western blotting confirmed proteins of the predicted molecular weights were 
expressed following transient transfection of Plat-E cells (Figure 1.12C). In 
addition Real Time PCR confirmed expression of fusion gene mRNA in 
retrovirally transduced bone marrow (Figure 1.12D).  
As shown in Figures 1.12E, similar numbers of tertiary colonies were observed 
when cells were transduced with MLL-AF9, MLL-1357-AF9 or MLL-1299-AF9.  
Further deletions of RD2 that extended more proximally than amino acid 1299, 
which markedly reduced PAFc interaction in our immunoprecipitation 
experiments (Figure 1.8), resulted in marked decreases in colony numbers 
(Figures 1.12E and 1.13). Importantly, the morphology of these colonies was also 
dramatically different. Tertiary colonies from MLL-AF9, MLL-1357-AF9 and MLL-





Figure 1.12 PAFc Interaction Region on RD2 Is Necessary for Bone Marrow 
Transformation (BMT) by MLL-AF9 (A) Schematic diagram for MLL-AF9 and MLL-AF9 
deletion BMT assay. (B) Constructs used for the BMT assay. Final amino acids of the 
MLL deletions are shown. (C) Protein levels of the FLAG-tagged MLL-AF9 deletions 
shown in B. LC: loading control. (D) Relative mRNA levels of the FLAG-tagged MLL-AF9 
deletions shown in B. Error bars indicate +/- SD. (E) Primary, secondary and tertiary 
colony counts are shown for BMT assays performed with the indicated MLL-AF9 fusion 
proteins. Error bars indicate SD from duplicate experiments. One of more than three 





Figure 1.13 p-Iodonitro Tetrazolium Violet (INT)-Stained Colonies after Three 
Rounds of Colony Replating. Dense red colonies are visible from MLL-AF9, MLL-
1299-AF9 and MLL-1357-AF9 transduced bone marrow. 
 
transformation (Lavau et al., 1997) (Figure 1.14A). Wright Giemsa-stained 
cytospins showed these compact colonies were composed of myeloblasts 
(Figure 1.14B). In contrast, transductions of constructs with more extensive 
deletions resulted in diffuse colonies composed of differentiating myeloid cells 
including monocytes and macrophages (Figures 1.13 and 1.14). Of note, MLL-
1258-AF9 retained a limited capacity to produce dense colonies after tertiary 
replating, but colony numbers were significantly reduced compared to MLL-AF9, 
MLL-1357-AF9 and MLL-1299-AF9 (Figures 1.13 and 1.14). In keeping with this, 






Figure 1.14 Morphology of Primary Bone Marrow Transduced by MLL-AF9 Fusion 
Proteins (A) Representative colony morphology is shown for each transduced MLL-AF9 
fusion protein. Dense colonies are indicative of transformation while diffuse colonies 
indicate differentiation. Scale bar = 500 µm (B) Wright-Giemsa stained cytospins on cells 




Figure 1.15 Hoxa9 Expression in Cells Collected after the Third Round of BMT 




We then used compared the Hoxa9 expression in cells transduced by wild-type 
MLL-AF9 and different deletion constructs. As expected, MLL-AF9, as well as 
1357 and 1299 deletions, markedly upregulated Hoxa9 expression, while forms 




Figure 1.16 Schematic Diagram for MLL-AF9 BMT Assay with shRNA-Mediated 
Knockdown of Cdc73 and Ctr9. BMT assays were performed as described in Figure 
1.12A, except for an additional transduction after the second replating with shScram, 
shCdc73 or shCtr9 retroviruses followed by plating in methylcellulose with puromycin 
selection. Colonies were scored after the third plating. 
 
To confirm PAFc is necessary for MLL-AF9 mediated transformation we 
performed colony assays by transducing primary bone marrow cells with MLL-
AF9 followed by a second round of transduction with shRNA retroviruses directed 
against Cdc73 or Ctr9 (Figure 1.16). Both shCdc73 and shCtr9 were confirmed to 
knock down Cdc73 and Ctr9, respectively, at both mRNA level and protein level 
(Figures 1.17A and 1.17B). Knockdown of either Cdc73 or Ctr9 resulted in 
significantly reduced colony formation compared to a scrambled control shRNA 
(Figure 1.17C). We also observed a moderate reduce in proliferation rate when 
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either Cdc73 or Ctr9 was knocked down in primary cells grown in liquid culture in 
the presence of IL3 and SCF (Figure 1.17D). Together, these data suggest the 
PAFc interaction with MLL is crucially important for both MLL fusion protein-
mediated Hox deregulation and transformation.  
 
 
Figure 1.17 Knockdown of Cdc73 or Ctr9 Impairs MLL-AF9-Induced Bone Marrow 
Transformation (A) RT-qPCR confirming knockdown of Cdc73 and Ctr9 mRNA, 
compared to the control, in 3T3 cells. Error bars indicate +/- SD. (B) Western blot 
confirming knockdown of Cdc73 and Ctr9 protein, compare to the control, in 3T3 cells. β-
actin serves as a loading control. (C) Third round colony counts following transduction 
with shScram, shCdc73 or shCtr9. Error bars indicate +/- SD. (D) Growth curve analysis 
of MLL-AF9-transduced primary bone marrow with knockdown by shCdc73 or shCtr9.  
 
PAFc Promotes MLL and MLL Fusion Protein Recruitment to Target Loci 
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We then examined the localization of PAFc to a leukemogenic target gene of 
MLL such as Hoxa9. For these experiments we generated cell lines by 
transducing mouse bone marrow with either MLL-ENL or E2A-HLF. MLL-ENL 
cells express much higher levels of both Hoxa9 and Meis1 compared to E2A-
HLF cells, which are not dependent on Hoxa9 expression for transformation 




Figure 1.18 RT-PCR for Hoxa9 and Meis1 Expression in MLL-ENL and E2A-HLF 
Cell lines. Error bars indicate +/- SD. 
 
We performed chromatin immunoprecipitation (ChIP) experiments for PAF 
components, PAF1, LEO1, CDC73 and CTR9 at the Hoxa9 locus in both cell 
lines (Figure 1.19). These experiments showed robust binding of MLL-ENL as 
detected by the ENL antibody in MLL-ENL cells compared to E2A-HLF cells 






Figure 1.19 PAFc and MLL-ENL Bind across the Hoxa9 Locus. ChIP experiment 
performed in mouse bone marrow cell lines established with the MLL-ENL or E2A-HLF 
fusion protein. MLL-ENL IPs are shown in black and H2A-HLF IPs are shown in green. 
Solid lines indicate the binding pattern of the component or histone modification listed to 
the right. The dotted lines indicate control IgG IPs for each cell line. The Hoxa9 locus is 
shown schematically at the bottom.   
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markedly elevated in MLL-ENL cells consistent with ENL mediated recruitment of 
DOT1L (Mueller et al., 2007). Similarly, we also observed binding of MLL-ENL 
and PAFc at the Meis1 locus in MLL-ENL cells, with minimal binding seen in 
E2A-HLF cells (Figure 1.20). Together, these data suggest that PAFc binds to 




Figure 1.20 PAFc and MLL-ENL Bind at the Meis1 Locus. ChIP experiment was 
performed as described in Figure 1.19, except that the binding on the Meis1 locus, 
instead of the Hoxa9 locus, was determined. 
 
To further evaluate the role of PAFc in transcriptional activation we measured the 
effect of PAFc subunit knockdown on MLL-AF9 mediated transcriptional 
activation. Knockdown of PAF1, LEO1, CDC73 and CTR9 was successfully 
achieved in HeLa cells using siRNA transfection (Figure 1.21A). As previously 
reported, PAFc knockdown decreases HOXA9 expression in HeLa cells (Figure 
1.21B) (Zhu et al., 2005b). Consistently, MLL-AF9 transcriptional activation of 
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Hoxa9-LUC is also impaired by PAF1, LEO1, CDC73 or CTR9 knockdown 
(Figure 1.21). Furthermore, we saw an additive effect by knocking down both 
CTR9 and LEO1 suggesting MLL fusion proteins require PAFc for efficient 




Figure 1.21 Knockdown of PAFc Reduces MLL-AF9-Induced Transactivation (A) 
siRNA-mediated knockdown of individual PAF components was verified by western 
blotting. (B) Luciferase assays were performed with the Hoxa9-LUC reporter construct 
and MLL-AF9 in HeLa cells after transfection with the indicated siRNA. Luciferase units 
are shown relative to the MigR1 control transfected cells.  
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We then determined the effect of knock down of the PAF complex on MLL 
recruitment to the HOXA9 locus by performing ChIP assays on HeLa cells after 
simultaneous knock down of CTR9, PAF1, CDC73 and LEO1 (Figure 1.22). We 
observed a significant decrease in binding of CDC73, PAF1 and LEO1 in both 
the promoter and coding region of the HOXA9 locus following knockdown, as 
expected, while histone H3 levels remain unchanged or elevated in siPAFc-
treated cells (Figure 1.23). PAFc knock down resulted in a marked decrease in 
wild-type MLL binding compared to mock treated cells (Figure 1.23), without 
affecting MLL protein levels (Figure 1.22), suggesting PAFc enhances MLL 
recruitment to HOXA9. Consistent with reduced binding of MLL, knock down of 
the PAF complex also resulted in a decrease in H3K4 tri-methylation at the 
HOXA9 locus (Figure 1.23). We also observed a decrease in histone H3K79 tri-
methylation (Figure 1.23). 
 
 
Figure 1.22 Simultaneous siRNA-Mediated Knockdown of PAFc (siCTR9, siLEO1, 
siPAF1 and siCDC73). β-ACTIN serves as the loading control.  
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Figure 1.23 Knockdown of 
PAFc Reduces MLL Binding 
to the HOXA9 Locus. ChIP 
experiments were performed in 
HeLa cells following 
simultaneous knockdown of 
PAFc shown in Figure 2.22. 
PAF1, LEO1, CDC73, MLLC, 
H3K4me3, H3K79me3 and H3 
were immunoprecipitated from 
HeLa cells treated with siPAFc 
or non-targeting siRNA (Mock). 
Binding was assessed in both 
the promoter and coding 
region as indicated. A 
schematic of the HOXA9 locus 
and location of the primer-
probe sets used for qPCR are 
shown. Error bars indicate +/- 
SD. One of more than three 





PAFc expression is coordinately downregulated during myeloid 
differentiation 
The above results suggest that the PAF complex enhances MLL recruitment to 
the HOXA9 locus and that modulating PAFc levels may be an important 
mechanism for modulating MLL activity. It is noteworthy in this regard that a 
recent unbiased genome-wide siRNA screen identified PAFc subunits Ctr9, 
Wdr61 and Rtf1 amongst the 30 top genes regulating Oct4 expression and stem 
cell renewal (Ding et al., 2009). In this study PAFc was found to bind to key 
pluripotency genes, which is remarkable because MLL fusion protein transformed 
cells show, in addition to HOX gene over expression, a distinctive embryonic 
stem cell (ESC)-like pluripotency signature (Somervaille et al., 2009). 
Furthermore, expression of PAFc subunits is strongly regulated upon 
differentiation of ESCs into embryoid bodies (Ding et al., 2009). Collectively, 
these findings suggested that PAFc might be positively involved in maintaining 
the relatively undifferentiated stage of hematopoietic progenitors.  
We established two differentiation models to explore the potential role of PAFc in 
regulation during hematopoietic differentiation. First, we created a conditional 
AML cell line by immortalizing murine bone marrow by transduction with Hoxa9-
ER in the presence of tamoxifen (4-OHT). Upon 4-OHT withdrawal, these cells 
undergo differentiation and cell cycle arrest, which is largely complete by 120 
hours (Figure 1.24). Microarray expression profiling was performed in triplicate at 
24, 48, 72, 96 and 120 hours following 4-OHT withdrawal (only results for 72, 96 
and 120 hours are shown in Figure 1.25A.  These experiments showed a marked 
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down regulation of all PAFc subunits and MLL target genes after induction of 
differentiation accompanied by up regulation of genes associated with myeloid 
differentiation (Figure 1.25A). The down regulation of PAFc expression was 




Figure 1.24 Differentiation of Hoxa9ER Cell Line Induced by 4-OHT Withdrawal (A) 
Growth curves for the Hoxa9ER cell line was determined in the presence and absence 
of tamoxifen (4OHT). B) Wright-Giemsa stained cytospins demonstrate the morphology 
of the Hoxa9ER cells in the presence of tamoxifen and 8 days post tamoxifen withdrawal. 






Figure 1.25 PAFc Is Downregulated during Differentiation of Hoxa9ER Cells 
Induced by 4-OHT Withdrawal (A) Heat map generated from expression array data 
collected from differentiation of the Hoxa9ER cell line. Data is shown in triplicate for each 
time point following tamoxifen withdrawal. Labels indicate components of the PAF 
complex, MLL and MLL targets, and genes associated with myeloid cell differentiation. B) 
Expression of PAF components were verified using qPCR by separately differentiating 
the Hoxa9ER cell line by tamoxifen withdrawal. Time points indicate hours post 
tamoxifen withdrawal that RNA was collected. Expression for each component is shown 
relative to 0 hours. Error bars indicate +/- SD. 
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We also analyzed the human HL-60 cell line, which rapidly differentiate into 
macrophages after exposure to phorbol 12-myristate 13-acetate (PMA) (Figure 
1.26A). PMA treatment also led to a dramatic down regulation of PAFc in HL-60 
cells (Figure 1.26B).  
 
 
Figure 1.26 PAFc Is Downregulated during Differentiation of HL-60 Cells Induced 
by PMA Treatment (A) Differentiation of the HL-60 cell line induced by PMA treatment 
was confirmed by Wright-Giemsa staining of cytospin preparations. Scale bars = 50 µm. 
(B) PAFc expression levels were determined by RT-PCR before and after PMA 






Figure 1.27 PAFc Overexpression in THP-1 Cells Leads to Resistance to 
Differentiation Induction by PMA Treatment (A) THP-1 cells were transfected with an 
equal mixture of PAFc expression vectors or empty vectors along with a GFP vector at a 
5:1 ratio (PAFc/Empty:GFP). Half were treated with PMA to induce differentiation. 
Surface expression of CD11b was monitored by FACS in the GFP positive gated cell 
population to track differentiation. Mean fluorescence values are shown for each sample. 
(B) THP-1 cells were transfected with empty vectors or PAFc together with a GFP 
expression vector. In contrast to the GFP positive population, CD11b expression was 
monitored on the GFP negative population which showed little to no change in 
expression with or without PMA treatment. 
 
To test the role of PAFc in hematopoietic differentiation, we enforced expression 
of PAFc in THP-1 cells with or without PMA induced differentiation. THP-1 cells 
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were more resistant to differentiation, as determined by CD11b surface 
expression, when PAFc was over expressed (Figure 1.27A). Importantly, GFP 
negative cells showed no significant difference in CD11b expression (Figure 
1.27B). Together, these data show PAFc expression is specifically down 
regulated during myeloid differentiation and that high level PAFc expression 
inhibits differentiation. Thus, PAFc may play an important role in regulating MLL 




Figure 1.28 Structure of the CxxC Domain and Flanking Sequences (PDB code: 
2JYI). Solution structure of MLL CxxC region shows the flanking sequences of the CxxC 
domain brought into close juxtaposition creating a binding surface for both PAF1 and 





The work presented here establishes PAFc as an important cofactor for both 
transcriptional regulation by MLL and for leukemogenesis mediated by MLL 
fusion proteins (Figure 1.29). By mass spectrum analysis, we demonstrated that 
PAFc interacts with the CxxC-RD2 region of MLL, a region that is always 
retained in MLL-rearranged oncoproteins. Detailed mapping revealed two 
interaction sites flanking the CxxC domain with two individual components of 
PAFc (Figure 1.28). Most importantly, we were able to show that the PAFc-MLL 
interaction enhances the transcriptional activation by MLL-AF9 and plays an 
indispensible role in MLL-AF9-induced leukemogenic transformation. 
Characterization of the PAFc-MLL interaction provides valuable insight into the 
mechanisms of MLL-rearranged leukemogenesis. The best-defined target genes 
of MLL are the clustered homeobox (Hox) genes, a transcription factor family 
important in cell fate determination during development. Among these targets, 
Hoxa9 and its cofactor Meis1 have been shown to be crucial for MLL-rearranged 
leukemogenesis. Normally, Hoxa9 and Meis1 are only briefly expressed in 
hematopoietic stem cell and progenitor cell populations and are then rapidly 
down regulated during hematopoietic differentiation (Lawrence et al., 1996; Magli 
et al., 1997; Zeisig et al., 2004). However, in the presence of MLL-rearranged 
oncoproteins, both remain expressed at high levels, which accounts for their 
leukemogenic capacity. Although many interaction partners of MLL-rearranged 






Figure 1.29 Functional Implication of the MLL-PAFc Interaction. (Top) PAFc-
dependent recruitment of MLL to target genes in hematopoietic progenitors 
(HSC/myeloblasts). PAFc and MLL recruitment promotes H2B mono-ubiquitination and 
H3K4 and H3K79 methylation resulting in transcriptional activation. (Middle) More 
differentiated myeloid cells down regulate PAFc expression resulting in decreased 
recruitment and transactivation by MLL. (Bottom) In leukemic cells harboring MLL fusion 
proteins the fusion protein synergizes with PAFc resulting in robust transcriptional 
activation of target genes. This is associated with increased H2B mono-ubiquitination 




remains unclear what are the exact molecular mechanisms responsible for the 
dysregulation of the expression of these target genes. 
Aside from our identification of the PAFc-MLL interaction, several lines of 
evidence also indicate the direct role of PAFc in Hox gene dysregulation in MLL-
rearranged leukemias. First, increasing evidence suggests that a significant 
mechanism for Hox gene expression is mediated through regulating 
transcriptional elongation (Chopra et al., 2009), a process in which PAFc has 
been known to play a key regulatory role (Jaehning, 2010b). Second, we 
observed a significant dose-dependent transcriptional activation of the Hoxa9 
promoter induced by MLL-AF9 overexpression, whereas wild-type MLL 
overexpression only delivered a somewhat more muted response, suggesting the 
differential roles of PAFc in cellular activities of MLL-rearranged oncoproteins vs. 
wild-type MLL. Third, a previous study by Chen et al. has demonstrated that the 
susceptibility of hematopoietic progenitors to MLL-AF9-induced transformation 
decreases along differentiation (Chen et al., 2008), consistent with the 
decreasing PAFc expression along hematopoietic differentiation shown by our 
work and others (Ding et al., 2009). Based on these findings, a potential 
mechanism for MLL-rearranged leukemogenesis is that by interacting with PAFc, 
MLL-rearranged oncoproteins are able to stably engage the basic transcription 
elongation machinery at target loci, such as Hoxa9 and Meis1, to constitutively 
activate transcription, leading to leukemogenesis. Therefore, PAFc may be a 
crucial component mediating the dysregulation of normal transcription elongation 





Figure 1.30 Schematic of a Potential Mechanism of MLL-Rearranged 
Leukemogenesis (top) In the absence of PAFc, RNA polymerase II (RNAP II) 
elongation is inhibited by the negative elongation factor (NELF) in collaboration with the 
DRB sensitivity-inducing factor DSIF. (middle) DSIF recruits PAFc that directly interacts 
with the E1/E2 ubiquitin ligase complex BRE1/RAD6, resulting in histone H2B 
monoubiquitination. Recruitment of positive transcription elongation factor b (P-TEFb) 
blocks the negative actions of NELF and DSIF by P-TEFb-dependent phosphorylation of 
RNAP II CTD and DSIF, priming the target promoter for transcription elongation (bottom) 
The interaction between PAFc and the most common MLL-rearranged oncoproteins 
(represented by MLL-AF9) recruits the ENL-associated proteins (EAPs) that include 
multiple common MLL translocation partners, DOT1L and P-TEFb to the target loci, 
promoting H2B monoubiquitination (  ), H3K4 methylation (  ) and H3K79 
methylation (  ), resulting in constitutively activated transcription. 
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Under normal conditions, Hoxa9 is expressed in primitive hematopoietic cells, 
playing a significant role in early hematopoiesis (Lawrence et al., 2005; Pineault 
et al., 2002). During hematopoietic differentiation, Hoxa9 expression is rapidly 
silenced, likely by pausing transcription elongation, an important mechanism 
regulating hox gene expression in Drosophila (Brookes and Pombo, 2009; 
Chopra et al., 2009). In this case, although RNA polymerase II (RNAP II) still 
localizes at the promoter region, its C-terminal domain (CTD) is 
unphosphorylated, and transcription elongation is inhibited by the negative 
elongation factor (NELF) in collaboration with the DRB sensitivity-inducing factor 
(DSIF) (Figure 1.30A). DSIF recruits PAFc that directly interacts with the E1/E2 
ubiquitin ligase complex BRE1/RAD6, resulting in histone H2B 
monoubiquitination. Meanwhile, the recruitment of the positive transcription 
elongation factor b (P-TEFb) reverts the negative actions of NELF and DSIF by 
P-TEFb-dependent phosphorylation of RNAP II CTD and DSIF (Jaehning, 
2010b). Thus, in the presence of PAFc, the target gene promoter region can 
progress to the active elongation stage (Figure 1.30B). It is worth noting that this 
status is probably a temporary transition stage, dynamically regulated by cell-
specific mechanisms, such as the abundance of PAFc, the binding affinity of 
other transcription elongation machinery components determined by the 
phosphorylation level of RNAP II CTD, the recruitment of histone 
methyltransferases, such as wild-type MLL and DOT1L, exerting H3K4 and 
H3K79 methylation, respectively, and the regulation of their enzymatic activities. 
For instance, in hematopoietic stem cells and early-stage progenitor cells, PAFc 
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is expressed at a high level; therefore, this temporary transition status is more 
likely to progress into a fully active elongation stage, which in turn leads to the 
Hox gene expression. In contrast, in the differentiated cells, PAFc 
downregulation may revert this transition status back to the inactive transcription 
stage, silencing the Hox gene expression. The dynamics of the multiple 
regulatory mechanisms is likely to be disrupted by MLL-rearranged oncoproteins, 
such as MLL-AF9. 
As previously mentioned, the most common MLL-rearranged oncoproteins, 
including MLL-AF9, MLL-ENL and MLL-AF4, are known to interact with the EAP 
complex or a closely related complex called AEP (Lin et al., 2010; Muntean et al., 
2010; Yokoyama et al., 2010). By interacting with PAFc, these MLL-rearranged 
oncoproteins recruits EAP that includes DOT1L, P-TEFb and multiple common 
MLL translocation partners to the target loci, promoting H3K79 methylation, 
resulting in dysregulated constitutively active gene expression (Figure 1.30C). In 
addition, wild-type MLL has recently been shown to synergize with MLL-AF9, 
which further increases the H3K4 methylation level and presumably contributes 
to target gene transcriptional activation (Thiel et al., 2010). Notably, in the study 
by Chen et al., the authors showed that LSK (Lin-Sca1+C-kit+) stem cells, but not 
the more differentiated committed granulocyte-monocyte progenitors (GMPs), 
can be transformed by MLL-AF9 under endogenous regulatory control, 
suggesting that under physiological conditions, additional linage-specific 
transcription factor(s) or coactivator(s), other than the MLL-rearranged 
oncoproteins, are critical for leukemogenesis (Chen et al., 2008). Given the 
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downregulation of PAFc during hematopoietic differentiation, it is possible that 
PAFc might partially accounts for the susceptibility of different progenitor 
populations to MLL fusion protein induced leukemogenesis.   
A number of questions remain regarding the mechanism of the PAFc-MLL 
interaction in MLL-rearranged leukemogenesis. First, apart from the most 
common MLL translocations resulting in MLL fusion proteins with a nuclear 
translocation partner, MLL fusion proteins with cytoplasmic partners and MLL-
PTD have not been extensively studied. Therefore, the leukemogenic 
mechanisms of MLL-PTD and MLL-rearranged oncoproteins with a cytoplasmic 
partner, both of which in effect involve duplication of the N-terminus of MLL (up to 
the breakpoint region) by either intramolecular partial tandem duplication or 
intermolecular dimerization, are unknown (Dou and Hess, 2008). Given the 
pivotal role of PAFc in MLL-rearranged leukemogenesis, it will be important to 
determine if either of these two types of MLL-rearranged oncoproteins involves 
enhanced physical or functional interaction with PAFc. Second, although our 
ChIP results suggest that both PAFc and MLL fusion protein bind to the target 
gene loci, such as Hoxa9 and Meis1, the specificity of this associated binding 
pattern warrants further investigation. For instance, whole genome ChIP-seq 
analysis of the binding sites of PAFc and MLL fusion proteins in MLL-rearranged 
leukemic cells will be important to determine how significant the overlapped 
binding might be, therefore better addressing whether the MLL-PAFc association 
only affects selected loci or plays a general role in the majority, if not all, of the 
downstream targets of MLL fusion proteins. Third, it is yet to be determined how, 
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and to what extent, PAFc plays differential roles in the cellular activities of MLL-
rearranged oncoproteins vs. wild-type MLL. It will be important to determine if 
such a therapeutic window exists for targeting PAFc, for example, through 
targeting the MLL-PAFc interaction with small molecule inhibitors, which could be 
used as a new therapy for MLL-rearranged leukemias. Last but not least, the 
data presented here primarily focused on the role of PAFc in one specific type of 
leukemia, MLL-rearranged leukemia. Since PAFc belongs to the basal 
transcriptional machinery that plays a general role in transcriptional regulation, it 
will be of therapeutic value to further explore whether PAFc is involved in the 
function of MLL-unrelated leukemogenic fusion proteins, therefore shedding light 
on the specificity of the role of PAFc in leukemogenesis. 
 
* The work presented in Chapter 1 was conducted in collaboration with Dr. 








PcG proteins were originally identified in Drosophila more than 30 years ago as 
regulators of anterior-posterior body patterning through the repression of 
homeobox (Hox) genes (Sauvageau and Sauvageau, 2010). They have since 
been recognized as evolutionarily conserved global epigenetic modifiers that 
antagonize the function of TrxG proteins. Generally, PcG proteins establish 
histone modifications that repress transcription, whereas TrxG proteins establish 
histone modifications that activate transcription (Mills, 2010). A number of studies 
have established the key regulatory roles of PcG proteins in multiple 
physiological processes, such as embryonic development, adult somatic cell 
differentiation, stem cell pluripotency and X chromosome inactivation (Bracken 
and Helin, 2009; Cao et al., 2011; Kanhere et al., 2010; Margueron and Reinberg, 
2011; Mills, 2010; Sauvageau and Sauvageau, 2010; Sparmann and van 
Lohuizen, 2006; Surface et al., 2010).  
The PcG family comprises a number of chromatin-associated complexes that are 





Figure 2.1 Diversity of PRC1 and PRC2 Complexes Formed by Vertebrate PcG 
Proteins. Subunits of the PRC1 (right panel) and PRC2 (left panel) complexes are 
indicated. The Drosophila homolog of each subunit is indicated in light blue. Multiple 
combinations of paralog subunits can generate a diversity of PRC1 and PRC2 
complexes, which likely have specific and shared functions. Some subunits seem to be 
present in substoichiometric amounts and interact with the PcG complexes in a cell-
context-dependent manner. The core subunits and the substoichiometric subunits are 
identified. The contacts illustrated in the diagrams are not intended to represent the 
actual interactions. Involvement of EPC and ASXL subunits with PRC2 or PRC1 
complexes is still unclear and requires further investigations. Adapted from (Sauvageau 
and Sauvageau, 2010). 
 
complexes, termed Polycomb Repressive Complexes (PRCs), is variable and 
context-dependent, which has been characterized in depth (Sauvageau and 
Sauvageau, 2010). In mammals, PRCs are mainly classified into two groups. 
One group is composed of the histone methyltransferase Enhancer of Zeste 
Homolog (EZH) 1 or EZH2 and its binding partners, Embryonic Ectoderm 
Development (EED) and Suppressor of Zeste 12 (SUZ12), which form the core of 
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the PRC2 complex (Figure 2.1, left panel) (Cao et al., 2002; Czermin et al., 2002; 
Kirmizis et al., 2004). Although not required for complex formation and stability, 
other proteins, such as PCL proteins, RBBP4/7 and JARID, have been identified 
as PRC2-associated cofactors that facilitate PRC2 functions (Landeira et al., 
2010; Nekrasov et al., 2007; Pasini et al., 2008; Peng et al., 2009). The core of 
the more heterogeneous PRC1 complex consists of one subunit of the PCGF, 
RING, CBX, PHC, and SCML paralog groups (Figure 2.1, right panel) (Levine et 
al., 2002; Valk-Lingbeek et al., 2004). Several less well-characterized 
components have also been reported to interact with the PRC1 core complex, 
including L3MBTL, SFMBT, and ASXL1 (Grimm et al., 2009; Ohtsubo et al., 2008; 
Peterson et al., 2004; Sanchez et al., 2007; Scheuermann et al., 2010).  
PRC-Mediated Transcriptional Silencing  
A wealth of genetic and biochemical studies have indicated that PRC complexes 
act as key engines for transcriptional silencing (Francis and Kingston, 2001; 
Levine et al., 2004; Muller and Verrijzer, 2009; Schuettengruber et al., 2007; 
Schwartz and Pirrotta, 2007; Simon and Kingston, 2009). However, the precise 
molecular mechanisms of PRC-mediated gene silencing are a challenging 
problem to solve due to the difficulty of reconstituting the native regulatory 
network in vitro and the combinatorial diversity of PRC1 complexes (Figure 2.1, 
right panel) (Kerppola, 2009). There has been evidence showing that PRC2 is 
involved in the recruitment of PRC1 to the promoter regions of their common 
targets for executing transcriptional repression (Kuzmichev et al., 2002; Tolhuis 
et al., 2006). Therefore, one prevailing hypothesis of PRC-mediated gene 
 63 
 
silencing is that the histone methyltransferase EZH1/2 of the PRC2 complex 
catalyzes the trimethylation of lysine 27 of histone H3 (H3K27me3). This typical 
epigenetic silencing mark can be recognized by chromobox homolog (CBX) 
proteins in PRC1 complexes, through which PRC1 is recruited to gene loci, 
which in turn enacts chromatin condensation, blocks the transcriptional 
elongation of RNA polymerase and finally leads to epigenetic silencing of target 
genes (Bracken and Helin, 2009; Cao et al., 2011; Simon and Kingston, 2009). 
The silencing effect is considered at least partially due to the monoubiquitination 
activity specific for the lysine 119 of H2A (H2AK119ub) by the enzymatic activity 
of the two core PRC1 components, RING1B and BMI1 (Figure 2.2) (Cao et al., 
2011; Wang et al., 2004).  
However, it has also been demonstrated that PRC1 and PRC2 can silence genes 
either synergistically or independently of each other (Richly et al., 2011). In fact, 
PRC1 recruitment to many sites occurs in the absence of PRC2 (Boyer et al., 
2006; Kerppola, 2009; Ku et al., 2008; Schoeftner et al., 2006). For example, 
Suz12-deficient embryonic stem (ES) cells lack detectable H3K27me3. However, 
during differentiation of these cells, Cbx8 and Bmi1 can still be recruited the 
majority of their target loci in WT ES cells (Pasini et al., 2007), suggesting that 
PRC1 localization can be regulated in a PRC2-independent manner. Indeed, a 
recent study has reported that the transcription factor REST regulates PRC1 
occupancy through interacting with CBX proteins, affecting the PRC1-mediated 
transcriptional silencing of genes with distal RE1 elements in ES cells (Ren and 






Figure 2.2 Coordinated Epigenetic Silencing Activity of PcG Complexes. Following 
recruitment of the PRC2 complex to chromatin, the histone methyltransferase EZH1/2 
catalyzes the trimethylation of the lysine 27 of histone H3 (H3K27me3). Subsequent 
recruitment of the PRC1 complex occurs in part through affinity binding of the 
chromodomain of the CBX subunit to the H3K27me3 covalent mark. The PRC1 RING1 
E3 ligase then monoubiquitylates the lysine 119 of histone H2A (H2AK119ub1), which 
was proposed to consolidate transcriptional repression by preventing access to 
chromatin remodelers, inhibiting RNA polymerase II-dependent transcriptional 
elongation and facilitating chromatin compaction (Francis et al., 2004; Zhou et al., 2008). 
PRC1 has also been reported to be targeted to chromatin independently of PRC2 (Boyer 
et al., 2006; Ku et al., 2008; Schoeftner et al., 2006). The ASXL subunit has recently 
been found to be involved in a H2A deubiquitinase complex required for PcG-mediated 
repression, but its precise role remains unclear. Adapted from (Sauvageau and 
Sauvageau, 2010).  
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the PRC2 component EZH2, have been reported to interact with DNA 
methyltransferases (DNMTs), suggesting that other than their direct enzymatic 
activities that induce transcriptional repression, PRC proteins may also contribute 
to gene silencing through recruiting DNMT to catalyze DNA methylation (Kim et 
al., 2008; Mohammad et al., 2009; Vire et al., 2006). 
PcG and Cancer 
The multifaceted regulatory functions of PcG proteins in key physiological 
processes during normal development strongly indicate that they are important 
players in oncogenesis. Indeed, both PRC1 and PRC2 components have been 
found to be overexpressed in a variety of tumors. On the one hand, expression 
changes associated with oncogenic transformation have been found for at least 
two core PRC1 proteins, BMI1 and RING1B, whose expression levels are 
elevated in a large series of tumors including gastrointestinal tumors, pituitary 
and parathyroid adenomas, and lymphomas, compared to the expression in 
normal cell counterparts (Sanchez-Beato et al., 2006). Especially, BMI1 activity is 
crucial for the maintenance of both normal and cancer stem cell because loss of 
BMI1 leads to progressive deletion of these cell population (Lessard and 
Sauvageau, 2003).  On the other hand, the PRC2 proteins are also 
overexpressed in multiple human cancers (Bracken and Helin, 2009; Sparmann 
and van Lohuizen, 2006). For instance, increased expression of EZH2 directly 
correlates to the invasive potential of multiple types of carcinomas, including 
bladder cancer, prostate cancer and breast cancer (Bachmann et al., 2006; 
Collett et al., 2006; Richly et al., 2011; Weikert et al., 2005). Moreover, EZH2 
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deregulation has been associated with the onset of colorectal cancer and oral 
squamous carcinomas (Kidani et al., 2009; Mimori et al., 2005).  
Other than transcriptional upregulation, missense mutations and chromosomal 
translocations involving PcG components have been identified in different types 
of human cancers as well (Sauvageau and Sauvageau, 2010). EZH2 mutations 
that alter its methyltransferase activity were found in germinal center diffuse large 
B cell lymphomas, follicular lymphomas and myeloid disorders (Ernst et al., 2010; 
Morin et al., 2010; Nikoloski et al., 2010). Moreover, Eed mutations in mice 
facilitate the formation and progression of lymphoid tumors (Richie et al., 2002), 
and a Suz12 point mutation has been shown to alter the repopulation capacity of 
the hematopoietic system (Majewski et al., 2008). Together, these studies 
emphasize that aberrant PRC2 activity is a frequent abnormality that contributes 
to oncogenesis. In addition, several PcG members, including the PRC1-
associated protein ASXL2, SUZ12 and PCL1, are involved in chromosomal 
translocations observed in human cancers such as acute leukemias and 
endometrial stromal sarcomas (Li et al., 2007; Nakahata et al., 2009). 
Aside from the transcriptional regulation and genetic mutations that alter the PRC 
activity, RNA-mediated regulatory mechanisms have also been found to gear 
PcG proteins towards tumorigenesis. First, the large intervening noncoding RNA 
(lincRNA) HOTAIR was reported to recruit the PRC2 complex for executing gene 
silencing (Gupta et al., 2010; Rinn et al., 2007). PRC2 relocalization in cancer 
cells due to HOTAIR overexpression promotes invasion and metastasis of 
epithelial tumors (Gupta et al., 2010). Additionally, the lincRNA ANRIL has been 
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shown to interact with the PRC1 component CBX7, which is required for the 
recruitment of PRC1 to the INK4A/ARF loci to induce transcriptional repression 
(Yap et al., 2010). These findings suggest that deregulated lincRNA-mediated 
PRC localization may contribute to the tumorigenic role of PcG proteins. Second, 
post-transcriptional regulation of PcG proteins by miRNAs has been well-
documented as an essential mechanism to modify PRC activities. Accumulated 
evidence suggest that increased PRC2 activity due to loss of miR-101 or miR-
26a promotes oncogenesis (Cao et al., 2011). Suppression of mir-183, mir-200c 
or mir-213, which leads to BMI1 upregulation, has been reported in several types 
of tumors (Sauvageau and Sauvageau, 2010). Furthermore, a recent study 
proposed a coordinate regulation of PRC1 and PRC2 activities mediated by 
miRNAs, which may play a significant role on cancer progression (Cao et al., 
2011). Taken together, multiple lines of evidence highlight the correlative role of 
PcG proteins in tumorigenesis. Abnormal PRC activities due to deregulated 
expression, somatic mutations, chromosomal translocations and aberrant 
recruitment of PRC1 and PRC2 are associated with cancer development, mainly 
because of the broad involvement of PRC complexes in major biological 
processes that are essential for both normal physiology and pathogenesis. 
CBX8 
Chromobox homolog 8 (CBX8), also known as HPC3 (Human Polycomb 3), 
belongs to the CBX protein family (including CBX2, 4, 6, 7 and 8) that are 
homologs of the Drosophila Polycomb (Pc) protein (Kerppola, 2009). CBX8 was 
originally characterized as a transcriptional repressor, interacting with RING1a/b 
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and associating with BMI1 in PRC1 (Bardos et al., 2000). A previous study has 
reported that as a PRC1 component, CBX8 represses the INK4a/ARF expression 
in fibroblasts (Dietrich et al., 2007). Further studies showed that several distinct 
PRC1 complexes colocalize and regulate the INK4a/ARF expression, suggesting 
that the INK4a/ARF locus is a general target for PRC1 complexes, rather than a 
CBX8-specific downstream target (Maertens et al., 2009). Therefore, the exact 
role of CBX8 in transcriptional regulation remains largely undefined. It has been 
reported that certain CBX proteins, such as CBX4, can associate with protein 
complexes other than PRC1, thereby playing a PRC1-independent role in 
transcriptional regulation (Kerppola, 2009). However, it remains unknown 
whether CBX8 has a PRC1-independent function as such, and if so, what the 
biological implication might be.  
Interestingly, despite its well-characterized transcription repressor role, CBX8 
has also been shown to be present in complexes recruited by MLL fusion 
proteins, which induces leukemogenesis through transcriptional activation 
(Monroe et al., 2010; Mueller et al., 2007). More specifically, CBX8 directly 
interacts with two of the most common MLL fusion partners, AF9 and ENL, both 
of which are transcription factors involved in gene activation (Garcia-Cuellar et al., 
2001; Hemenway et al., 2001; Monroe et al., 2010). However, the functional 
significance of this seemingly paradoxical association has not yet been defined, 
therefore raising the question that what the role of CBX8 plays in MLL-mediated 
leukemogenesis. 
HIV Tat interacting protein of 60 kDa 
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HIV Tat interacting protein of 60 kDa (TIP60) is a founding member of the MYST 
(Moz, Ybf2/Sas3, Sas2, Tip60) protein family, the largest family of histone 
acetyltransferases (HATs) that are highly conserved in all eukaryotes (Voss and 
Thomas, 2009). TIP60 is the catalytic subunit of the evolutionarily conserved 
NuA4 (nucleosome acetyltransferase of histone H4) complex (Doyon et al., 2004). 
Previous studies have shown that TIP60, in the context of the stable multi-protein 
complex, selectively acetylates nucleosomal H4 at lysines 5, 8, 12, and 16, as 
well as H2A, in vitro (Ikura et al., 2000; Sapountzi et al., 2006). Evidence from 
Drosophila indicates that modified histone variants, such as phospho-H2Av, can 
also be acetylated by TIP60 (Kusch et al., 2004). Apart from these histone 
substrates, TIP60 also has by far the most known non-histone targets. The 
majority of these substrates are transcription factors (Sapountzi and Cote, 2011). 
For example, one of the extensively studied non-histone substrates of TIP60 is 
the tumor suppressor p53. TIP60 can specifically acetylates lysine 120 (K120) of 
p53 upon DNA damage, thereby modulating the decision between cell cycle 
arrest and apoptosis upon p53 activation and by co-activating p53-driven 
transcription (Berns et al., 2004; Doyon et al., 2004; Legube et al., 2004; Sykes 
et al., 2006; Tang et al., 2006).  Other transcription factors whose activity is 
regulated by TIP60-mediated acetylation include c-Myc (Patel et al., 2004), RB 
(Leduc et al., 2006), and androgen receptor (Brady et al., 1999; Gaughan et al., 
2001; Gaughan et al., 2002). In addition to transcription factors, it has been 
shown that the ATM kinase, a key player in the DNA repair pathway, is also 
subjected to TIP60-mediated acetylation (Sun et al., 2005).  
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The broad spectrum of its acetylated substrates indicates that TIP60 plays a role 
in multiple biological processes. First, it is critically involved in DNA repair, mainly 
through the TIP60-p53 functional interaction, acetylation-mediated ATM 
activation, and TIP60-related H2Av modification (Avvakumov and Cote, 2007). 
Second, TIP60 has been well-characterized as a transcriptional co-activator in 
multiple key signaling pathways, such as c-Myc signaling, Wnt signaling, NF-κB 
signaling, and androgen receptor signaling (Baek et al., 2002; Frank et al., 2003; 
Sapountzi et al., 2006; Sierra et al., 2006). Although in the majority of cases, 
TIP60 has been associated with transcription activation, it has also been reported 
to induce gene repression in a context-dependent manner. For instance, TIP60 
can interact with HDAC to modulate STAT3 activity (Xiao et al., 2003). The 
multiple roles of TIP60 in DNA repair and transcriptional regulation have linked it 
to a number of human diseases, including HIV infection and Acquired Immune 
Deficiency Syndrome (AIDS), Alzheimer’s disease, and cancer (Avvakumov and 
Cote, 2007; Baek et al., 2002; Cao and Sudhof, 2001; Creaven et al., 1999; 
Kinoshita et al., 2002). A wealth of studies have suggested the involvement of 
TIP60 in oncogenesis, although in many of these cases, the direct mechanistic 
evidence is still lacking (Figure 2.3) (Avvakumov and Cote, 2007).  
It is worth noting that so far, TIP60 has not been shown to be involved in 
chromosomal translocation, which is the most common cause of human 
leukemias. However, it can act as a transcriptional regulator when interacting 
with TEL, which fuses with AML1 in the majority of childhood leukemias (So and 
van der Reijden, 2008). An additional study shows that TIP60 directly interacts 
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with the myeloid transcription factor C/EBPα in vitro and associates with C/EBPα 
at target gene loci in human leukemic cell lines (Bararia et al., 2008). The authors 
further suggested that TIP60 acts as a transcriptional co-activator of C/EBPα in 
an acetyltransferase-dependent manner by luciferase reporter assays (Bararia et 
al., 2008), raising the intriguing question of whether, and if so how, TIP60 might 




Figure 2.3 Established and Putative Connections of Tip60 to Oncogenesis. Green 
text boxes denote anti-oncogenic activities, whereas red ones represent potentially pro-
oncogenic connections. Solid lines link Tip60 with other NuA4 subunits, whereas dashed 
lines signify physical or functional interactions with other cellular proteins. Adapted from 
(Avvakumov and Cote, 2007). 
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Materials and Methods 
Cell Culture and Animal Use 
HeLa and 293 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and non-essential 
amino acids. MLL-AF9, MLL-ENL and E2A-HLF cells were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 15% fetal calf serum 
(FCS, Stem Cell Technologies). THP-1, Mono Mac 6 (MM6), and K562 cells 
were cultured in RPMI-1640 medium supplemented with 10% FBS. The Tripz-
RFP-shCBX8 expression was induced by 0.5 µg/ml doxycycline. For conditional 
knockout of Cbx8 in mice, two LoxP sites were inserted to flank the exons 2 to 4 
of the Cbx8 gene. Cbx8 excision was achieved upon 4-OHT treatment. Full 
details of conditional gene targeting of Cbx8 and analysis of Cbx8−/− embryos will 
be provided in a subsequent manuscript (H.K., unpublished). All animal 
experiments in this study were approved by the University of Michigan 
Committee on Use and Care of Animals and Unit for Laboratory Animal Medicine 
(ULAM). 
In Vivo Leukemogenesis Assays 
Lin- BM was isolated from 6 to 8-week-old mice (Cbx8 f/f; Cre+) injected with 5-
fluorouacil (see Supplemental Information). The harvested Lin- BM cells were 
retrovirally transduced with MigR1-MLL-AF9 by two rounds of spinoculation in the 
presence of either 4-OHT (100 nM) or ethanol as a control. The cells were then 
counted and injected intravenously through the tail vein to cohorts of lethally 
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irradiated (900 rads) C57BL/6 mice (3.5 x 104 cells per injection). Recipient mice 
were maintained on antibiotics for 2 weeks after transplantation. 
Complete Blood Count Analysis 
Peripheral blood was harvested in EDTA (ethylenediaminetetraacetic acid)-
containing Microtainer tubes (BD Biosciences) and subjected for analysis 
performed by the ULAM laboratory.  
Vector Construction 
The pfMLL-AF9 vector and pMSCV-neo constructs encoding MLL-AF9 were 
previously described (Muntean et al., 2010). The FLAG-CBX8 and HA-DOT1L 
constructs were generously provided by Dr. Robert Slany (University of Erlangen, 
Germany). Expression vectors for MLL-AF9 mutants and CxxC-AF9 mutants 
(T542A and T554A) were generated by restriction enzyme digestion and PCR-
based mutagenesis. The pSM2c scrambled, pSM2c shCbx8 (clone ID 
V2MM_66688), pSM2c shRing1b (clone IDs V2MM_197123 and V2MM_83055), 
pSM2c shBmi1 (clone ID V2HS_48576) and pSM2c shTip60 (clone ID 
V2MM_92042) retroviral vectors and the pTRIPZ-shCBX8 lentiviral vector (clone 
ID V2THS_58819) were purchased from Open Biosystems. An additional shRNA 
set for Tip60 knockdown based on the pGFP-V-RS retroviral vector system 
(Catalog Numbers TG512714 and TG30013) was purchased from OriGene. 
Immunoprecipitation and Immunoblotting Assays 
Cell lysates preparation, immunoprecipitation and immunoblotting were 
performed as previously described (Muntean et al., 2010). Immunoprecipitation 
was performed overnight, followed by three times of wash using BC-300 buffer. 
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Proteins were eluted by boiling in 1X SDS-loading buffer and separated by SDS-
PAGE, followed by western blot analysis. Primary antibodies included rabbit anti-
FLAG (Sigma), goat anti-Myc (Abcam), rabbit anti-HA (Abcam), rabbit anti-AF9 
(Bethyl Laboratories, Inc.), mouse anti-β-actin (Sigma), rabbit anti-CBX8 (Abcam), 
goat anti-CBX8 (Everest Biotech), mouse anti-MLL N (Millipore), mouse anti-
Bmi1 (Millipore), mouse anti-Ring1b (Medical and Biological Laboratories), and 
goat anti-TIP60 (Santa Cruz). An agarose affinity beads coupled to mouse anti-
FLAG M2 monoclonal antibody was purchased from Sigma. An agarose affinity 
beads coupled to mouse anti-Myc M2 monoclonal antibody was purchased from 
Clontech. Protein G agarose beads were purchased from Roche.  
Virus Production for Bone Marrow Transformation (BMT) Assays 
The pMSCV (for FLAG-MLL-AF9 and the mutants), pSM2c (for shScram, shCbx8, 
shRing1b-1, shRing1b-2, shBmi1 and shTip60) and pGFP-V-RS (for shScram-1 
and shTip60-1) constructs were transfected using Fugene 6 reagent (Roche) into 
Plat-E cells selected in puromycin (1 µg/ml) and blasticidin (10 µg/ml). Media 
containing the recombinant retrovirus was collected for transduction at 48 and 72 
hours post transfection. Lentivirus production was performed by the University of 
Michigan Vector Core. Medium containing virus was collected 48 h post 
transfection. 
BMT Assays 
BMT assays were performed as previously described, with some modifications 
(Muntean et al., 2010). Briefly, BM was harvested from 6 to 8-week-old mice 
(Cbx8 f/f; Cre+, or Cbx8 f/f; Cre-) injected with 5-fluorouacil. Cells were collected 
 75 
 
from the tibia and femur. Lin- BM cells were isolated using the EasySep® Mouse 
Hematopoietic Progenitor Cell Enrichment Kit (STEMCELL Technologies). The 
cells were then transduced with recombinant retrovirus containing MLL-AF9 (WT 
or mutants) by spinoculation and plated in methylcellulose medium (M3234, 
STEMCELL Technologies), supplemented with IL-3, IL-6, SCF, GM-CSF and 1 
mg/ml G418. After three rounds of plating, CFU (with > 50 cells) was scored 
under the microscope; colonies were stained using 0.1% INT and scanned. Cells 
harvested at the end of the experiment were cytospun and stained with the Hema 
3 Stain Kit (Thermo Fisher Scientific). Images were acquired using a 100x lens 
under an Olympus BX-51 microscope (Olympus). For secondary transductions, 
MLL-AF9-transduced cells harvested after the third round of plating were 
transduced with the indicated shRNA retrovirus by spinoculation and plated as 
described above, using 2 µg/ml puromycin in methylcellulose medium for 
selection. For in vitro Cbx8 excision, cells were treated with 100 nM 4-OHT 
(Sigma) either during transduction (pre-transformation excision) or after three 
rounds of plating (post-transformation excision).  
Colony Formation Assays 
For assessing the total hematopoietic progenitor cell activity, BM was harvested 
from Cbx8 f/f; Cre+ mice 6 months after in vivo 4-OHT administration or corn oil 
control treatment. After red blood cell lysis using ACK lysis buffer (Cambrex), 
nucleated BM cells were counted and plated in methylcellulose medium (M3534, 




Reverse transcription and quantitative PCR were performed as previously 
described (Muntean et al., 2010). FLAG-MLL-AF9 was detected using the 
following primers for SYBR green detection: FLAG-F-5’-ggactacaaggacgacgatga-
3’ and MLL-R-5’-acagctgtgcgccatgtt-3’. TaqMan primer probe sets were 
purchased from Applied Biosystems for mouse Hoxa9, Cbx8, Ring1b, Bmi1, 
Tip60, Ink4a/Arf and β-actin, as well as human HOXA9, CBX8, TIP60 and β-
ACTIN. Expression levels were analyzed using the comparative ΔΔCt method as 
described in ABI User Bulletin #2.  
Luciferase Reporter Assays  
293 cells were transiently transfected with MSCV, MLL-AF9 (WT and mutants), 
CMV-Renilla, and Hoxa9-LUC (or Myc E box-LUC) constructs using FuGene 6 
(Roche) according to the manufacturer’s instructions. The cells then underwent 
serum starvation in 0.5% FBS in OPTI-MEM media for 48 h. Luciferase reporter 
assays were performed using a Dual Luciferase assay kit (Promega) according 
to manufacturer’s instructions. Emission was detected using a Monolight 3010 
luminometer (BD Biosciences). For the luciferase assay with siRNA knockdown, 
HeLa cells were transiently transfected with the DNA constructs listed above 
using Lipofectamine (Invitrogen) and siRNA smart pools for targeting CBX8, 
RING1b, BMI1 and TIP60 (Dharmacon) using Oligofectamine (Invitrogen) 
according to the manufacturer’s instructions. The firefly luciferase activity 




ChIP was performed as previously described (Milne et al., 2005b), using primary 
antibodies for CBX8 (Abcam), Cbx8 (also named as Mpc3, Santa Cruz), RNAP II 
(Covance), TIP60 (Santa Cruz), AF9 (Bethyl Laboratories, Inc.) and histone H3 
(Abcam). Quantitative RT-PCR was performed on the precipitated DNAs using 
primers and qPCR probes described before (Muntean et al., 2010). Binding was 
quantitated as follows: ΔCT = CT(input) − CT(Chromatin IP), % total = 2ΔCT. 
Annexin V Staining 
For apoptosis analysis, MLL-AF9 leukemic cells from Cbx8 f/f; Cre+ and Cbx8 f/f; 
Cre- mice were treated with 4-OHT (100 nM) for 72 h, using ethanol as a control 
treatment. The treated cells were washed and resuspended in Annexin V binding 
buffer (BD Biosciences). The resuspended cells were stained with Annexin V-
FITC (BioLegend) and 1 µg/ml DAPI. Stained cells were then analyzed by flow 
cytometry. 
Cell Cycle Analysis 
MLL-AF9 leukemic cells from Cbx8 f/f; Cre+ and Cbx8 f/f; Cre- mice were treated 
with 4-OHT (100 nM) for 72 h, using ethanol as a control treatment. The treated 
cells were washed twice in phosphate buffered saline (PBS). The cells were then 
resuspended in ice-cold PBS and fixed in 70% ethanol for at least 24 h. The fixed 
cells were washed with standard buffer for flow cytometry, treated with 100 µg/ml 
RNase and stained with 10 µg/ml PI. Stained cells were then analyzed by flow 
cytometry. 
Competitive Transplantation Assays 
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Competitive transplantation assays were performed as previously described, with 
some modifications (Maillard et al., 2009). Briefly, BM was harvested from Cbx8 
f/f; Cre+ mice 6 months after in vivo 4-OHT administration or corn oil control 
treatment. After red blood cell lysis using ACK lysis buffer (Cambrex), nucleated 
BM cells were counted and resuspended in ice-cold phosphate-buffered saline 
(PBS). These cells (CD45.2+) were mixed at specific ratios with 5 x 
105 CD45.1+ competitor BM cells from B6-SJL mice (1:1, 3:1 and 9:1). This 
mixture was injected intravenously through the tail vein to cohorts of lethally 
irradiated (900 rads) B6-SJL (B6-CD45.1) mice. Recipient mice were maintained 
on antibiotics for 2 weeks after transplantation, and their peripheral blood was 
assessed by flow cytometry. 
Flow Cytometry and Cell Sorting 
After blocking non-specific binding with unlabeled rat plus mouse IgG (Sigma-
Aldrich), cells were stained on ice in PBS plus 4% fetal calf serum (FCS) and 
sorted on FACSAria (BD Biosciences). Analysis was performed on LSR II, 
FACSCanto, or FACSAria (BD Biosciences). Files were analyzed in FlowJo 
(TreeStar). 
Statistical Analysis 
Statistical significance was determined by Student’s t test using the Excel 
software (Microsoft 2007); p< 0.05 was considered statistically significant. 
Antibodies for Flow Cytometry Analysis 
The antibodies used for flow cytometry analysis were obtained from BioLegend 
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CBX8 Specifically Interacts with MLL-AF9 at the C-Terminal Domain (CTD) 
Previous studies have reported that the MLL fusion partner AF9 directly interacts 
with CBX8 through the evolutionarily conserved CTD (Figure 2.4A) (Garcia-
Cuellar et al., 2001; Hemenway et al., 2001; Monroe et al., 2010). However, 
whether this interaction is retained in MLL-AF9 fusion protein has not been 
defined. To address this question, we transiently co-expressed epitope-tagged 
MLL-AF9 and CBX8 in human embryonic kidney 293 cells, using a FLAG-tagged 
“empty” vector as a negative control. Specific interaction between CBX8 and 
MLL-AF9 was detected by immunoprecipitation (IP) experiments. When using 
AF9-conjugated agarose beads to pull down the full-length fusion protein, we 
consistently observed that CBX8 coprecipitated with MLL-AF9 (Figure 2.4B). To 
further characterize this interaction, we performed IP experiments in the 
presence of Benzonase. Using anti-FLAG antibody to pull down FLAG-tagged 
MLL-AF9, we detected endogenous CBX8 coprecipitating with the fusion protein, 
suggesting that CBX8 interacts with MLL-AF9 in a DNA-independent manner 
(Figures 2.4C). Next, we characterized the critical CBX8 interaction sites on MLL-
AF9, by generating 15 point mutants within the CTD through single amino acid 
substitution. By Co-IP experiments, we identified two point mutants (T542A and 
T554A) that specifically disrupt the CBX8 interaction (Figures 2.4A and 2.4D). 
This observation was further supported by reciprocal Co-IP experiments, using 
anti-FLAG or anti-Myc antibodies to pull down CBX8 or CxxC-AF9, respectively 





Figure 2.4 CBX8 Specifically Interacts with MLL-AF9 at the C-terminal Domain 
(CTD) (A) Schematic of full-length MLL-AF9. The amino acid sequence of the 
evolutionarily conserved CTD of AF9 is aligned with Drosophila, Rattus norvegicus and 
Mus musculus AF9 homologs. Red arrows indicate the evolutionarily-conserved 
threonine residues converted to alanine used below. (B) Co-immunoprecipitation of 
FLAG-tagged CBX8 with fMLL-AF9 (f-MA9). (C) Co-immunoprecipitation of endogenous 
CBX8 with f-MA9, after Benzonase treatment. (D) Co-immunoprecipitation of 
endogenous CBX8 with WT FLAG-MA9, but not with the mutants (T542A and T554A). 
(E) Co-immunoprecipitation of FLAG-CBX8 with WT Myc-CxxC-AF9, but not the mutants. 
(F) Reciprocal IP of the experiments in (E). WT Myc-CxxC-AF9 or the mutants were 
coexpressed with FLAG-CBX8, followed by IP with an anti-Myc antibody. Western blot 
shows that the interaction between Myc-CxxC-AF9 and FLAG- CBX8 is disrupted in the 
mutants. A fraction (3%) of cell lysate was used for input control.  
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MLL-AF9 fragment, was used as a surrogate for the full-length fusion protein 
(Muntean et al., 2010).  
Apart from CBX8, AF9 also associates either directly or indirectly with DOT1L, 
the P-TEFb complex (CDK9 and CYCLINT1) and AF5q31 (Monroe et al., 2010). 
Therefore, we asked whether the CBX8 interaction is required for interaction with 
any of these cofactors. To this end, we transiently transfected Myc-tagged CxxC-
AF9 (WT or the mutants) in 293 cells and found that the P-TEFb complex (CDK9 
and CYCLINT1) and AF5q31 coprecipitated with both the WT CxxC-AF9 
fragment and the mutants (Figure 2.5D). Moreover, the interaction between 
DOT1L and CxxC-AF9 was also retained in the T542A and T554A mutants, as 
shown by reciprocal IP experiments using anti-FLAG or anti-HA antibodies to pull 
down CBX8 or DOT1L, respectively (Figures 2.5A and 2.5B). This observation 
was further confirmed by IP experiments in the context of full-length MLL-AF9 
(Figure 2.5C). Together, our results showed that CBX8 specifically interacts with 
MLL-AF9 at the CTD, and that disrupting the CBX8 interaction does not affect the 
interaction with either P-TEFb or DOT1L, both of which are required for MLL-
AF9-induced leukemogenesis. It is noteworthy that these data did not address 
the possibility of whether P-TEFb and/or DOT1L might affect the interaction 
between CBX8 and MLL-AF9. 
CBX8 Is Essential for Both Initiation and Maintenance of MLL-AF9 
Leukemic Transformation 
To assess the importance of the CBX8 interaction in MLL-AF9-induced 
transformation, we first used bone marrow transformation (BMT) assays to 
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examine the transformation ability of the MLL-AF9 mutants (T542A and T554A), 




Figure 2.5 Specific Disruption of the CBX8 Interaction Does not Affect the 
Interaction between DOT1L and MLL-AF9 (A) Co-immunoprecipitation of both WT 
Myc-CxxC-AF9 and the mutants with HA-DOT1L. (B) WT Myc-CxxC-AF9 or the mutants 
were coexpressed with HA- DOT1L, followed by IP with an anti-Myc antibody. Western 
blot shows HA- DOT1L coprecipitating with both WT Myc-CxxC-AF9 and the mutants. (C) 
WT FLAG-MA9 or the FLAG-MA9 mutants were coexpressed with HA-DOT1L, followed 
by IP with an anti-HA antibody. Western blot shows HA- DOT1L coprecipitating with both 
WT FLAG-MA9 and the mutants. (D) Co-immunoprecipitation of endogenous CDK9, 
CYCLIN T1 and AF5q31 with both WT Myc-CxxC-AF9 and the mutants. All of the Co-IP 
experiments included an epitope-tagged empty vector (FLAG-V or Myc-V) as a control 




primary murine bone marrow (BM) were retrovirally transduced with either WT 
MLL-AF9 or the mutants, followed by three consecutive rounds of plating (Figure 
2.6A). Despite the comparable expression of the fusion transcripts, as confirmed 
by real-time quantitative polymerase chain reaction (RT-PCR), the T542A and 
T554A mutations completely abolished myeloid transformation, whereas the WT 
control potently transformed primary hematopoietic cells, forming a large number 
of colonies (Figures 2.6B and 2.6C). The tertiary colonies formed by WT MLL-
AF9-transduced cells displayed a dense, compact morphology, indicative of 
immortalization. Wright Giemsa staining shows that these colonies are composed 
of myeloblasts (Figure 2.6D). In contrast, the MLL-AF9 mutant-transduced cells 
failed to form colonies in the second round of selection, and the residual living 
cells were composed primarily of monocytes and macrophages (Figure 2.6D).  
To further confirm that Cbx8 is required for MLL-AF9-induced transformation, we 
transduced the MLL-AF9-transformed BM cells with either the control shRNA or a 
shRNA directed against Cbx8 after the third round plating, followed by puromycin 
selection (Figure 2.7A). Cbx8 expression, as measured by RT-qPCR, was 
effectively downregulated (Figure 2.7B), whereas the MLL-AF9 expression level 
was not significantly affected (p>0.05, Figure 2.7C). As expected, knockdown of 
Cbx8 significantly reduced the colony formation ability of MLL-AF9-transduced 
cells, compared to the control (p<0.01, Figures 2.7D and 2.7E). Together, these 
results suggest that the CBX8/MLL-AF9 interaction is required for MLL-AF9-





Figure 2.6 CBX8/MLL-AF9 Interaction Is Essential for MLL-AF9 Leukemic 
Transformation (A) Experimental scheme of the BMT assays evaluating the leukemic 
transformation ability of WT MLL-AF9 and MLL-AF9 mutants (T542A and T554A). (B) 
RT-qPCR analysis of the expression levels of WT MLL-AF9 and the mutants in Lin- BM 
after retroviral transduction. (C) Colony-forming units (CFU) per 20,000 plated cells in 
each round of plating in methylcellulose. Error bars represent ± standard deviation (SD) 
from three independent experiments. (D) Morphology of representative colonies from 
primary BM cells transduced with indicated constructs. The first row shows the 
representative colony morphology in methylcellulose. Scale bar, 500 µm. The second 
row shows the p-iodonitro tetrazolium violet (INT)-stained colonies after two rounds of 
plating. Dense red colonies are visible from WT MLL-AF9. The third row shows the 






Figure 2.7 Cbx8 Knockdown by shRNA Impairs MLL-AF9 Leukemic 
Transformation (A) Experimental scheme of the BMT assays with shRNA-mediated 
Cbx8 knockdown. Experiments were performed as described in Figure 2.6, except for an 
additional retroviral transduction of shCbx8 or the control construct, followed by one 
round of plating with puromycin selection, after three rounds of plating. CFU was scored 
after the fourth plating. (B) RT-PCR analysis of Cbx8 expression in MLL-AF9-
transformed primary BM transduced with shCbx8 compared to the control, confirming 
the efficiency of CBX8 knockdown. (C) RT-PCR analysis of MLL-AF9 expression in MLL-
AF9-transformed primary BM transduced with shCbx8, compared to the control. (D) 
Relative CFU of MLL-AF9-transformed primary BM transduced with shCbx8, compared 
to the control. Error bars represent ± SD from three independent experiments. (E) 
Representative INT-stained colonies in methylcellulose after the fourth round of plating.  
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We then used a conditional Cbx8 knockout mouse model (generated by Dr. 
Koseki) to further assess the role of Cbx8 in initiation and maintenance of 
transformation by MLL-fusion proteins in vitro and in vivo (Figure 2.8A). Cbx8f/f 
mice were bred with Rosa26-Cre-ERT2 mice to generate Cbx8 conditional 
knockout mice. Treatment with 4-hydroxyltamoxifen (4-OHT) induced efficient 
Cbx8 excision in primary BM cells from Cbx8 f/f; Cre+ mice (Figure 2.8B).  
 
 
Figure 2.8 Strategy of Conditional Knockdown of Cbx8 in Mice (A) Schematic 
showing the floxed Cbx8 and the primers used for detecting the floxed and the excised 
Cbx8. (B) Genotype analysis showing the efficiency of Cbx8 excision induced by 4-OHT 
treatment in primary BM from Cbx8 f/f; Cre+ mice, with ethanol treatment as a control 
(EtOH). 
 
To assess the role of Cbx8 in initiation and maintenance of MLL-AF9 leukemic 
transformation, we induced Cbx8 excision by 4-OHT treatment, simultaneously 
with MLL-AF9 transduction or after selecting MLL-AF9-transformed cells by three 
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consecutive rounds of plating, respectively, with BM from Cbx8f/f; Cre- mice 




Figure 2.9 Experimental Scheme for the BMT Assays with Cbx8 Excision in 
Primary BM from Cbx8 f/f; Cre+ and Cbx8 f/f; Cre- Mice. The first experimental 
procedure was performed as described in Figure 2.6A, except 4-OHT or ethanol was 
added during MLL-AF9 retroviral transduction. The second experiment was performed 
as described in Figure 2.7A, except using 4-OHT treatment instead of shCbx8 
transduction. 
 
The expression level of MLL-AF9 was not significantly altered by 4-OHT 
treatment in either of these experimental settings (Figures 2.10A and 2.10B). 
Strikingly, loss of Cbx8 completely abolished colony formation by MLL-AF9-
transduced cells under both conditions (Figures 2.10C-2.10E). In contrast to the 
colonies formed by Cbx8f/f; Cre+ cells with the control treatment and the Cbx8f/f; 
Cre- control cells with or without 4-OHT treatment, which showed dense 
morphology and were composed predominantly of myeloblasts (Figure 2.10G), 
Cbx8-depleted cells failed to form colonies and were composed of monocytes 
and macrophages (Figure 2.10F). Together, our results strongly indicate that 
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Figure 2.10 Cbx8 Is Required for Both Initiation and Maintenance of MLL-AF9 
Leukemic Transformation (A and B) RT-PCR analysis of MLL-AF9 expression in Lin- 
BM after retroviral transduction, in the two experiment settings shown in Figure 2.9. Error 
bars represent ± SD from two independent experiments. Each experiment was 
performed in duplicate. (C) CFU per 20,000 plated cells in each round of plating in 
methylcellulose. Error bars represent ± SD from two independent experiments. Each 
experiment was performed in duplicate. (D and E) Relative CFU of MLL-AF9-transduced 
cells in the two experimental settings. Error bars represent ± SD from two independent 
experiments. (F) Representative INT-stained colonies in methylcellulose. (G) Wright-




Given our findings with the BMT assay, an in vitro surrogate for assessing 
myeloid transformation ability (Cheung et al., 2007; Lavau et al., 1997; Smith et 
al., 2011), we then tested the role of Cbx8 in MLL-AF9 leukemogenesis in vivo. 
The MigR1-MLL-AF9 construct, which expresses both MLL-AF9 and GFP, was 
used to retrovirally transduce Lin- BM cells derived from the Cbx8f/f; Cre+ mice, in 
the presence or absence of 4-OHT. These cells were then transplanted into 
syngeneic mice for accessing their leukemogenic potential. Complete Cbx8 
excision in the donor cells was achieved by 4-OHT treatment, as confirmed by 
genotyping the peripheral blood of the recipient mice three weeks post transplant 
(Figure 2.11A). Consistent with our in vitro findings, mice receiving Cbx8-
deficient, MLL-AF9-transduced cells failed to develop leukemia, whereas mice 
receiving WT MLL-AF9-transduced BM all died from leukemia, as evidenced by 
marked splenomegaly and extensive infiltration of peripheral blood, spleen and 
liver (Figures 2.11B-2.11D). As expected, flow cytometry analysis showed that 
BM from the leukemic mice was replaced by GFP-positive, MLL-AF9-transformed 
cells (>99%). In contrast, BM from the mice receiving Cbx8-depleted donor cells 
was negative for GFP expression (Figure 2.11E). These results strongly 
demonstrate that CBX8 is required for MLL-AF9-induced leukemogenesis.  
Notable, a previous study has shown that CBX8 also interacts with another MLL 
fusion partner, ENL, which is also a component of the EAP (or the related AEP) 
complex (Garcia-Cuellar et al., 2001). Therefore, it is likely that CBX8 is not only 
required for MLL-AF9 leukemogenesis but also involved in leukemic 





Figure 2.11 Cbx8 Is Required for MLL-AF9-Induced Leukemogenesis in Vivo. (A) 
Genotype analysis of peripheral blood from recipient mice transplanted with Cbx8 f/f or 
Cbx8 ∆/∆ donor BM three weeks post transplant. (B) Representative pictures of spleens 
harvested from recipient mice transplanted with Cbx8 f/f or Cbx8 ∆/∆ donor BM. (C) Wright-
Giemsa staining of peripheral blood (PB) smear and BM and histology of liver and 
spleen from the transplanted mice. (D) Kaplan-Meier survival analysis of mice 
transplanted with Cbx8 ∆/∆ (n=5) or Cbx8 f/f (n=5) donor BM. (E) GFP expression of BM 
from the transplanted mice, assessed by flow cytometry.  
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 related AEP and the Dotcom) complex, such as MLL-ENL. Indeed, similar to 
MLL-AF9, Cbx8 is essential for initiation and maintenance of leukemic 
transformation induced by MLL-ENL, as shown by BMT assays (Figures 2.12A-
2.12D). This finding suggests that the dependence on CBX8 of leukemic 
transformation is not restricted to MLL-AF9 but may apply to other MLL fusion 
proteins as well. 
CBX8 Is Crucial for Proliferation and Survival of MLL-AF9-transformed 
Leukemic Cells and for MLL-AF9-Induced Transcriptional Activation 
To explore the underlying mechanisms of Cbx8-dependent oncogenic 
transformation, we first investigated whether the Cbx8 dependence is specific for 
certain MLL-rearranged transformation or for leukemic transformation in general. 
Using the conditional Cbx8 knockout mice, we assessed the impact of Cbx8 
deletion on leukemic transformation by E2A-HLF, a leukemogenic fusion protein 
that transforms through Hox-independent pathways (Ayton and Cleary, 2003). 
Despite the complete depletion of the Cbx8 protein achieved 4-OHT treatment, 
neither the initiation nor the maintenance of E2A-HLF-induced leukemic 
transformation was affected, suggesting the specificity of Cbx8-dependent 
transformation (Figures 2.12E-2.12H and 2.13). Together, these findings suggest 
that Cbx8 plays a specific role in leukemic transformation by certain MLL fusion 
proteins, such as MLL-AF9. 
We then examined whether Cbx8 is important in regulating the proliferation of 
MLL-AF9 leukemic cells and found that the Cbx8 shRNA, but not the scrambled 





Figure 2.12 Cbx8 Is Required for the Leukemic Transformation by MLL-ENL, but 
not for That by E2A-HLF (A and B) Relative CFU of MLL-ENL-transduced cells in the 
two experimental settings. Error bars represent ± SD from two independent experiments. 
Each experiment was performed in duplicate. (C) INT-stained colonies after 
transformation selection, following MLL-ENL retroviral transduction. (D) Wright-Giemsa-
stained cells isolated after transformation selection, following MLL-ENL retroviral 
transduction. Scale bar, 30 µm. (E and F) Relative CFU of E2A-HLF-transduced cells in 
the two experimental settings. (G) INT-stained colonies after transformation selection, 
following E2A-HLF retroviral transduction. (H) Wright-Giemsa-stained cells isolated after 






Figure 2.13 Western Blot Showing the Cbx8 Protein Level upon 4-OHT Treatment 




Figure 2.14 CBX8 Is Crucial for Proliferation and Survival of MLL-AF9-transformed 
Leukemic Cells (A) Growth curve of MLL-AF9 leukemic cells transduced with shCbx8 or 
control (shScram). Error bars represent ± SD from duplicate experiments. Results from 
one of three independent experiments are shown. (B and C) Growth curves of MLL-AF9-
transformed primary BM from Cbx8 f/f; Cre+ and Cbx8 f/f; Cre- mice, with 4-OHT treatment 
compared to the control. Error bars represent ± SD from a duplicate experiment. Results 
from one of two independent experiments are shown. 
 
The phenotype was even more dramatic in primary murine BM cells, where we 
observed a complete growth arrest in liquid cultured primary BM cells (Cbx8f/f; 
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Cre+) with Cbx8 excision by 4-OHT treatment, whereas no such effect was 
observed in control cells (Cbx8f/f; Cre- ) (Figures 2.14B and 2.14C). In agreement 
with these observations, the apoptotic population of MLL-AF9 leukemic cells 
increased upon Cbx8 depletion by 4-OHT treatment, but not in the control cells 
(Figure 2.15). Additionally, we consistently observed a slight decrease of the S-
phase cell population upon Cbx8 depletion in MLL-AF9 leukemic cells (Figure 
2.16). However, the effect was rather minor, suggesting that the dramatic 
proliferation defect of MLL-AF9 cells upon Cbx8 depletion is not mainly due to 
cell cycle arrest. 
 
 
Figure 2.15 Apoptosis Analysis of MLL-AF9 Leukemic Cell in the Presence or 
Absence of Cbx8 The proportion of annexin V-positive, DAPI-negative cells from MLL-
AF9-transformed leukemic cells (Cbx8 f/f; Cre+ and Cbx8 f/f; Cre-), after 72-h 4-OHT 

















Figure 2.16 Cell Cycle Analysis of MLL-AF9 Leukemic Cell in the Presence or 
Absence of Cbx8. Cell cycle analysis was performed on MLL-AF9-transformed 
leukemic cells (Cbx8 f/f; Cre+ and Cbx8 f/f; Cre-), after 72-h 4-OHT treatment, using 
ethanol treatment as a control. 
 
A well-established oncogenic mechanism of MLL-AF9 transformation is the 
constitutive activation of the HOX genes, particularly HOXA9 along with the HOX 
cofactor MEIS1 (Armstrong et al., 2002; Ayton and Cleary, 2003; Kumar et al., 
2004), whereas CBX8 was previously shown to be involved in transcriptional 
repression (Dietrich et al., 2007; Maertens et al., 2009). The seemingly opposite 
effects of CBX8 and MLL-AF9 on transcriptional regulation raise an intriguing 
question: what role does CBX8 play in MLL-AF9-induced transcriptional 
activation? To address this question, we examined Hoxa9 expression in MLL-
AF9-transformed primary BM transduced with the Cbx8 shRNA. Compared to the 
control, Cbx8 downregulation led to a marked suppression of Hoxa9 expression 
(Figure 2.17A). A similar effect was observed in MLL-AF9-transformed Cbx8f/f; 
Cre+ BM, following Cbx8 excision by 4-OHT treatment, but not in the control cells 
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(Figures 2.17B and 2.17C). To further confirm that the impact of Cbx8 on Hoxa9 
expression is dependent on the interaction between Cbx8 and MLL-AF9, we 
compared the Hoxa9 expression in primary BM cells transduced by WT MLL-AF9 
or by the mutants lacking the Cbx8 interaction (T542A and T554A). Notably, 
MLL-AF9 mutant-transduced cells show significantly reduced Hoxa9 expression, 
compared to the cells transduced by WT MLL-AF9 (Figure 2.17D). It is 
noteworthy that the cells examined in this experiment were harvested after the 
second round of selection because very few mutant-transformed cells survive the 
third round of selection. Therefore, few residual non-transformed progenitors may 
account for the detected Hoxa9 expression in the mutant-transformed cells, 
suggesting that the reduction of Hoxa9 expression in the mutant-transduced cells 
could be even greater. Nevertheless, these data strongly indicate that Cbx8 
serves as a co-activator of MLL-AF9, promoting Hoxa9 upregulation in MLL-AF9-
transformed cells.  
To further assess the specificity of the role of Cbx8 in Hoxa9 transcriptional 
regulation, we examined the effect of Cbx8 knockdown on Hoxa9 expression in 
several human and murine leukemic cell lines. CBX8 inducible knockdown stable 
cell lines were generated by lentiviral transduction of a TRIPZ-RFP-shCBX8 
construct in three human leukemic cell lines. The THP-1 and Mono Mac 6 (MM 6) 
cells are transformed by MLL-AF9, whereas K562 is a BCR-ABL-transformed cell 
line that serves as a control. As expected, knocking down of CBX8 induced by 






Figure 2.17 Cbx8 Is required for Hoxa9 Upregulation in MLL-AF9-Transformed 
Primary BM Cells (A) RT-PCR analysis of the expression of Cbx8 and Hoxa9 in MLL-
AF9-transformed primary BM, with shCbx8 transduction compared to the control 
(shScram). (B) RT-qPCR analysis of the expression of Cbx8 and Hoxa9 in MLL-AF9-
transformed primary BM from Cbx8 f/f; Cre+ mice, with 4-OHT treatment compared to the 
control (EtOH). (C) RT-PCR analysis of the expression of Cbx8 and Hoxa9 in MLL-AF9-
transformed primary BM from Cbx8 f/f; Cre- mice, with 4-OHT treatment compared to the 
control (EtOH). Error bars represent ± SD. (D) RT-PCR analysis of the Hoxa9 
expression in primary BM transduced by WT MLL-AF9 or MLL-AF9 mutants, compared 





Figure 2.18 Cbx8 Is required for Hoxa9 Upregulation in Human and Murine MLL-
AF9-Transformed Leukemic Cell Lines (A) RT-PCR analysis of the expression of 
Cbx8 and Hoxa9 in two human MLL-AF9 leukemic cell lines (THP-1 and MM 6) and one 
MLL-independent human leukemic cell line (K562), with shRNA-mediated CBX8 
knockdown. These three cell lines were integrated with a TRIPZ-RFP-shCBX8 construct 
by lentiviral transduction, whose expression can be induced by doxycycline treatment. 
Error bars represent ± SD. (B) RT-PCR analysis of the expression of Cbx8 and Hoxa9 in 
a MLL-AF9 murine leukemic cell line and an E2A-HLF murine leukemic cell line, with 




MLL- AF9-transformed cell lines (MM 6 and THP-1), but not in the control cell line 
(Figure 2.18A). Consistent with this observation, Cbx8 knockdown by shRNA led 
to a marked decrease of Hoxa9 expression in a murine MLL-AF9 cell line, but not 
in the Hoxa9-independent E2A-HLF cell line (Figure 2.18B). These findings 
suggest that Cbx8 specifically contributes to MLL-AF9-induced Hoxa9 
transcriptional activation.  
In order to mechanistically understand how Cbx8 facilitates MLL-AF9-induced 
Hoxa9 upregulation, we investigated the effect of Cbx8 on Hoxa9 promoter 
activity in the presence of MLL-AF9. We first performed dual luciferase assays in 
293 cells transfected with a MLL-AF9 responsive luciferase construct, under the 
control of the murine Hoxa9 promoter (Hoxa9-LUC). Our data show that 
disrupting the CBX8 interaction by the point mutation of T542A or T554A 
significantly decreased the activation of the Hoxa9 promoter by MLL-AF9 (T542A: 
p<0.01, T554A: p<0.01; Figure 2.19A). Consistent with this result, knocking down 
the CBX8 expression by siRNAs reduced the MLL-AF9 induced transcriptional 
activation by around 50% (p<0.01, Figures 2.19B and 2.19G). A similar response 
was observed using another MLL-AF9 responsive luciferase reporter containing 
the thymidine kinase promoter and multimerized Myc E box, further supporting 
the importance of Cbx8 in MLL-AF9-induced transcriptional activation (Figures 
2.19C and 2.19D). Notably, neither the point mutations nor CBX8 knockdown 
significantly affected MLL-AF9 expression, indicating that the reduction in Hoxa9 
promoter activity was not due to a general decrease in the MLL-AF9 level 





Figure 2.19 CBX8 Is Crucial for MLL-AF9-Induced Transcriptional Activation (A) 
Luciferase assay with a Hoxa9 promoter-driven reporter activated by WT or mutant MLL-
AF9 (T542A and T554A) in 293 cells. Error bars represent ± SD from three independent 
experiments. (B) Luciferase assay with the Hoxa9 promoter-driven reporter activated by 
MLL-AF9, with CBX8 knockdown (siCBX8) or control treatment (siScram) in HeLa cells. 
Error bars represent ± SD from three independent experiments. (C) Luciferase assay 
with a Myc E box promoter-driven reporter activated by WT or mutant MLL-AF9 (T542A 
and T554A) in 293 cells. Error bars represent ± SD from three independent experiments. 
(D) Luciferase assay with the Myc E-box promoter-driven reporter activated by MLL-AF9, 
with CBX8 knockdown (siCBX8) or control treatment (siScram) in HeLa cells. Error bars 
represent ± SD from three independent experiments. (E) RT-PCR analysis of the 
expression of WT MLL-AF9 and the mutants in luciferase reporter assay. (F) RT-PCR 
analysis of MLL-AF9 expression in luciferase reporter assay, with siCBX8 treatment 
compared to the control (siScram). (G) Western blot showing CBX8 expression with 
siCBX8 treatment compared to the control (siScram).   
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We then carried out chromatin immunoprecipitation (ChIP) in MLL-AF9-
transformed murine hematopoietic cells, to examine changes at the Hoxa9 
promoter in response to Cbx8 depletion. In agreement with the suppression of 
Hoxa9 activation, a significant decrease of RNA polymerase II (RNAP II) binding 
to the Hoxa9 promoter was detected following Cbx8 depletion by 4-OHT 
treatment, while as expected, Cbx8 binding was essentially ablated (Figures 
2.20A and 2.20B). Moreover, the collective binding of MLL-AF9 fusion protein 
and WT AF9 was not affected by Cbx8 depletion, as shown by ChIP with an anti-
AF9 antibody (Figure 2.20C). Because WT AF9 is also a component of the MLL-
AF9 complex, and our previous results already showed that the Cbx8 interaction 
is not required for the assembly between the EAP complex and the MLL-AF9 
fusion protein (Figure 2.5), this observation suggest that the recruitment of the 
MLL-AF9 complex to the Hoxa9 promoter is not significantly affected by the loss 
of Cbx8, which is also consistent with previous reports regarding the importance 
of the retaining MLL portion in MLL fusion complex localization, rather than the 
fusion partner portion (Ayton et al., 2004; Milne et al., 2010; Muntean et al., 2010; 
Slany et al., 1998; Yokoyama and Cleary, 2008). Similar findings were observed 
using the CBX8 inducible knockdown MM6 cell line (Figures 2.20E-2.20J), further 
supporting that Cbx8 regulates MLL-AF9 target promoter activity, thereby 
contributing to MLL-AF9-induced transcriptional activation, without affecting the 






Figure 2.20 Cbx8 Is not Required for the collective localization of MLL-AF9 and WT 
AF9 at the Hoxa9 Promoter (A-D) Relative binding of Cbx8, RNAP II and MLL-AF9 
together with WT AF9, as well as H3 binding, to the Hoxa9 promoter in MLL-AF9-
transformed cells from Cbx8 f/f; Cre+ mice, with 4-OHT treatment compared to the control 
(EtOH). (E-H) Relative binding of CBX8, RNAP II and MLL-AF9 together with WT AF9, 
as well as H3 binding, to the HOXA9 promoter in TRIPZ-RFP-shCBX8-containing MM6 
cells, with doxycycline treatment compared to the control. Error bars represent ± SD 
from three independent experiments. (I) RFP expression induced by doxycycline 
treatment, indicating shRNA induction. Scale bars = 100 µm. (J) Western blot showing 
the CBX8 protein level in TRIPZ-RFP-shCBX8-containing MM 6 cells after doxycycline 
treatment, using β-ACTIN as a loading control. 
 104 
 
Role of CBX8 in MLL-AF9 Leukemic Transformation and Transcriptional 
Activation Is Independent of PRC1 
To date, the only reported functional characterization of Cbx8 is its role as a 
transcriptional repressor in PRC1, whereas our data indicate that Cbx8 serves as 
a transcriptional coactivator in the presence of MLL-AF9. These opposing 
transcriptional regulatory roles suggest that Cbx8 functions in a PRC1-
independent manner in MLL-AF9 leukemic transformation. It has been shown 
that Ring1b, another PRC1 component, is required for the stability of PRC1 
complexes (Leeb and Wutz, 2007; van der Stoop et al., 2008). In addition, 
previous studies have indicated that Ring1b also interacts with AF9 (Monroe et 
al., 2010), which we confirmed by IP experiments showing that endogenous 
RING1b consistently coprecipitates with the MLL-AF9 fragment, CxxC-AF9 
(Figure 2.21A). Therefore, to test our hypothesis of the potential PRC1-
independent function of Cbx8, we first assessed the impact of Ring1b on MLL-
AF9 leukemic transformation by BMT assays. Two individual shRNA molecules 
specifically targeting Ring1b were used to effectively knock down Ring1b 
expression in MLL-AF9-transformed leukemic cells. Reduction in Ring1b 
expression in these experiments did not impair the transformation ability of MLL-
AF9 (Figures 2.21B, 2.21C and 2.21F). Knocking down Ring1b did not 
significantly affect the growth rate or Hoxa9 expression in MLL-AF9 cells either 
(Figures 2.21D and 2.21E). We also performed dual luciferase assays to 





Figure 2.21 Ring1b Knockdown Does not Recapitulate the Effects of Cbx8 
Knockdown on MLL-AF9 Leukemic Transformation (A) Co-immunoprecipitation of 
endogenous RING1b with Myc-CxxC-AF9 in 293 cells. A fraction (3%) of cell lysate was 
used for input control. (B) Relative CFU of MLL-AF9 leukemic cells with Ring1b 
knockdown by two individual shRing1b molecules, compared to the control (shScram). 
Error bars represent ± SD from three independent experiments. (C) Representative INT-
stained colonies in methylcellulose. (D) Growth curve of MLL-AF9 leukemic cells with 
Ring1b knockdown, compared to the control. Error bars represent ± SD from a duplicate 
experiment. Results from one of three independent experiments are shown. (E) RT-PCR 
analysis of Hoxa9 expression in MLL-AF9 leukemic cells with Ring1b knockdown, 
compared to the control. (F) RT-PCR analysis of Ring1b expression in MLL-AF9 






Figure 2.22 Ring1b Knockdown Does not Recapitulate the Effects of Cbx8 
Knockdown on MLL-AF9-Induced Transactivation of the Target Promoters (A and 
B) Experiments were performed as described in Figures 2.19B and 2.19D, except using 
siRNAs specifically targeting RING1b (siRING1b) in place of siCBX8. Error bars 
represent ± SD from three independent experiments. (C) Western blot showing RING1b 
expression with siRING1b treatment, compared to the control (siScram).  
 
promoter activity. Despite the marked reduction of RING1b expression shown by 
western-blot analysis, MLL-AF9-induced transactivation of the target promoters 
was not suppressed by RING1b knockdown (Figures 2.22A-2.22C). Similar to 
our observations with Ring1b, knockdown of Bmi1, another core PRC1 
component, did not affect the transformation ability, growth rate or transcriptional 
activation in MLL-AF9 leukemic cells (Figures 2.23-2.24). Consistent with these 
observations, Cbx8 depletion in MLL-AF9-transformed BM cells did not affect the 
global levels of Ring1b and Bmi1, as shown by western-blot analysis (Figure 
2.23A). Taken together, these findings suggest that Cbx8 functions as an MLL-




Figure 2.23 Bmi1 Knockdown Does not Recapitulate the Effects of Cbx8 
Knockdown in MLL-AF9 Leukemic Transformation (A) Western blots showing the 
expression of Cbx8, Bmi1 and Ring1b in MLL-AF9-transformed cells from Cbx8 f/f; Cre+ 
mice, with 4-OHT treatment compared to the control (EtOH). (B) Relative CFU of MLL-
AF9 leukemic cells with Bmi1 knockdown by shBmi1 transduction, compared to the 
control. Error bars represent ± SD from three independent experiments. (C) 
Representative INT-stained colonies in methylcellulose. (D) Growth curve of MLL-AF9 
leukemic cells with Bmi1 knockdown, compared to the control. Error bars represent ± SD 
from a duplicate experiment. Results from one of three independent experiments are 
shown. (E) RT-PCR analysis of Hoxa9 expression in MLL-AF9 leukemic cells with Bmi1 
knockdown, compared to the control. (F) RT-PCR analysis of Bmi1 expression in MLL-






Figure 2.24 Bmi1 Knockdown Does not Recapitulate the Effects of Cbx8 
Knockdown on MLL-AF9-Induced Transactivation of the Target Promoters (A and 
B) Experiments were performed as described in Figures 2.19B and 2.19D, except using 
siRNAs specifically targeting Bmi1 (siBmi1) instead of siRING1b. Error bars represent ± 
SD from three independent experiments. (C) Western blot showing BMI1 expression 
with siBMI1 treatment, compared to the control (siScram), using β-ACTIN as a loading 
control. 
 
CBX8 Regulation of TIP60 Localization Contributes to MLL-AF9 Leukemic 
Transformation 
The characterization of the PRC1 independence of Cbx8 functions in MLL-AF9 
leukemic transformation prompted us to explore the possible involvement of 
other Cbx8 interacting proteins that may explain the role of Cbx8 in 
transcriptional activation. A previous study has reported that CBX8 directly 
interacts with the histone acetyltransferase (HAT) TIP60 by high-throughput 
yeast two-hybrid screens and mass spectroscopy analysis (Stelzl et al., 2005). 
However, this observation has not yet been verified in any mammalian cell 
 109 
 
system; therefore, the functional implication of this interaction remains an open 
question. To first confirm this interaction, we transiently expressed FLAG-tagged 
CBX8 in 293 cells. Specific interaction between CBX8 and TIP60 was detected 
by IP experiments: using anti-FLAG antibody to pull down CBX8, we observed 
that CBX8 consistently coprecipitated with endogenous TIP60 in the presence of 
Benzonase, indicating CBX8 interacts with TIP60 in a DNA-independent manner 
(Figures 2.25A and 2.25A). This finding implied an intriguing possibility that 
CBX8 promotes MLL-AF9 leukemic transformation, at least partially through its 
interaction with the transcriptional coactivator TIP60. To test this hypothesis, we 
first assessed the impact of Tip60 on MLL-AF9 leukemic transformation by BMT 
assays. Using shRNA molecules specifically targeting Tip60, we observed a 
reduction in the colony formation ability of MLL-AF9 leukemic cells (Figures 
2.25B, 2.25C and 2.25F). Moreover, Tip60 downregulation by shRNA led to a 
decrease in the growth rate and Hoxa9 expression of MLL-AF9-transformed cells 
(Figures 2.25D and 2.25E). Similar results were obtained using a different 
shRNA pool, further supporting that Tip60 positively contributes to MLL-AF9 
leukemic transformation (Figures 2.26B-2.26F).  
To further characterize the role of Tip60 in MLL-AF9-induced transcriptional 
activation, we performed dual luciferase assays to examine the impact of TIP60 
downregulation by siRNA on the MLL-AF9 target promoter activity. A significant 
reduction of TIP60 expression was confirmed by western-blot analysis (Figure 
2.27D). As expected, the MLL-AF9-induced transcriptional activation of the target 





Figure 2.25 CBX8 Interacts with TIP60, Whose Downregulation Phenocopies the 
Effects of Cbx8 Knockdown on MLL-AF9 Leukemic Transformation (A) Co-
immunoprecipitation of endogenous TIP60 with FLAG-CBX8 in 293 cells, after 
Benzonase treatment. A fraction (3%) of cell lysate was used for input control. (B) 
Relative CFU of MLL-AF9 leukemic cells with Tip60 knockdown by shRNA, compared to 
the control (shScram). Error bars represent ± SD from three independent experiments. 
(C) Representative INT-stained colonies in methylcellulose. (D) Growth curve of MLL-
AF9 leukemic cells with Tip60 knockdown, compared to the control. Error bars represent 
± SD from a duplicate experiment. Results from one of three independent experiments 
are shown. (E) RT-PCR analysis of Hoxa9 expression in MLL-AF9 leukemic cells with 
Tip60 knockdown, compared to the control. (F) RT-PCR analysis of Tip60 expression in 





Figure 2.26 Tip60 Knockdown Phenocopies the Effects of Cbx8 Knockdown in 
MLL-AF9 Leukemic Transformation (A) Lysates from the experiment shown in Figure 
2.25A were treated with Benzonase. Ethidium bromide staining of an agarose gel shows 
complete DNA digestion after Benzonase treatment. (B-F) Experiments were performed 
as described in Figures 2.25B-2.25F, using a separate shRNA set specifically targeting 






Figure 2.27 Cbx8 Affects Tip60 Binding, Whose Downregulation Phenocopies the 
Effects of Cbx8 Knockdown on MLL-AF9-Induced Transactivation of the Target 
Promoters (A and B) Experiments were performed as described in Figures 2.16B and 
2.16D, except using siRNAs specifically targeting TIP60 (siTIP60) instead of siCBX8. 
Error bars represent ± SD from three independent experiments. (C) RT-qPCR analysis 
of MLL-AF9 expression in luciferase reporter assays, with siCBX8 treatment compared 
to the control (siScram). (D) Western blot analysis showing the TIP60 protein level in 
luciferase reporter assays with siTIP60 treatment, compared to the control (siScram), 
using β-ACTIN as a loading control. (E) Relative binding of Tip60 to the Hoxa9 promoter 
in MLL-AF9-transformed cells from Cbx8 f/f; Cre+ mice, with Cbx8 excision induced by 4-
OHT treatment compared to the control (EtOH). (F) Relative binding of TIP60 to the 
HOXA9 promoter in TRIPZ-RFP-shCBX8-containing MM 6 cells, with CBX8 knockdown 
induced by doxycycline treatment compared to the control. Error bars represent ± SD 




2.27C). Collectively, these data demonstrate that knocking down Tip60 
phenocopies the effect of Cbx8 knockdown in MLL-AF9 leukemic cells, 
suggesting a functional significance of the CBX8/TIP60 interaction in MLL-AF9 
leukemic transformation. To confirm the observed role of Tip60 is indeed 
associated to the CBX8/TIP60 interaction, we performed ChIP assays in MLL-
AF9-transformed leukemic cells, following Cbx8 depletion by 4-OHT treatment. 
As expected, Cbx8 depletion resulted in decreased Tip60 binding at the Hoxa9 
promoter (Figure 2.27E). Similar findings were seen using MLL-AF9-transformed 
cell lines, MM6, engineered for inducible knockdown of CBX8. In these cells, 
TIP60 binding at the Hoxa9 promoter was significantly reduced upon CBX8 
downregulation induced by doxycycline treatment (Figure 2.27F). Together, our 
results suggest that CBX8 affects TIP60 binding, which plays a positive role in 
MLL-AF9 leukemic transformation. 
Cbx8 Is not Required for Normal Hematopoiesis  
The profound impact of Cbx8 on MLL-AF9 leukemogenesis prompted us to 
examine the role of Cbx8 in normal hematopoiesis. We examined the effect of 
Cbx8 depletion during steady-state hematopoiesis in vivo. Constitutive depletion 
of Cbx8 showed no aberrant phenotype, and deletion of Cbx8 by 4-OHT 
treatment in adult animals had no detectable effect on any measured peripheral 
blood population as measured by complete blood count (CBC) analysis (Figure 
2.28). Moreover, both the cellularity of major hematopoietic organs (BM, spleen 
and thymus) and the cell number of mature hematopoietic populations as defined 





Figure 2.28 Cbx8-Depleted Mice Shows No Abnormality in the CBC Analysis of 
Peripheral Blood (A) Ethidium bromide-stained agarose gel showing the 4-OHT-
induced excision of the floxed Cbx8. At the starting and end points of the experiment, 
peripheral blood from Cbx8 f/f; Cre+ mice treated with 4-OHT or corn oil as a control was 
collected, from which genomic DNA was extracted and subjected to PCR analysis. (B-E) 
Peripheral blood CBC analysis of (B) platelets, (C) white blood cells, (D) red blood cells, 






Figure 2.29 Cbx8-Depleted Mice Shows Normality Cellularity of Major 
Hematopoietic Organs and Mature Hematopoietic Populations (A-D) Absolute 
quantification of total bone marrow cellularity (A), erythroid cells (Ter119+; B), 
developing B lymphocytes (AA4.1+CD19+B220+; C), and myeloid cells (CD11b+Gr1+; 
D) from Cbx8 f/f and Cbx8 ∆/∆, analyzed by flow cytometry (bars represent mean + SD; 
n=5 mice/genotype). (C-E) Absolute quantification of total splenocytes (C), thymocytes 
(D), double-positive T cells (CD4+CD8+; E) analyzed by flow cytometry revealed no 
significant difference between Cbx8 floxed (f/f) and deleted (Δ/Δ) mice (bars represent 




mice and controls (Figure 2.29). To address potential effects of Cbx8 deletion on 
primitive long-term hematopoietic stem cells (LT-HSCs), we combined flow 
cytometry for characterization of progenitor populations and competitive BM 
transplantation assays. These analyses revealed no detectable differences in LT-
HSC numbers (Figure 2.30) or hematopoietic reconstitution ability of Cbx8 WT or 
deficient BM in lethally irradiated recipients (Figure 2.31A). In addition, the total 
progenitor output from the BM of Cbx8-deficient animals was similar to controls, 
as measure by colony forming unit assays (Figures 2.31B and 2.31C). Together, 
these findings indicate that Cbx8 is not required for steady state hematopoiesis, 




Figure 2.30 Cbx8-Depleted Mice Shows No Abnormality in Maintaining the 
Primitive Long-Term Hematopoietic Stem Cell (LT-HSC) Population. Flow 
cytometric analysis of LT-HSCs (CD150+CD48-LSK) from Cbx8 f/f and Cbx8 ∆/∆ mice 






Figure 2.31 Cbx8-Depleted Mice Shows Normal Stem and Progenitor Cell Function 
(A) Competitive BM transplantation at competitor: tester ratios of 1:1 (n=10/group), 1:3 
(n=5 mice per group), and 1:9 (n=5 mice per group).  No difference between Cbx8 f/f and 
Cbx8 ∆/∆ mice was observed in tester contribution to myeloid reconstitution at any ratio 
(data represent mean ± SD). (B) Colony forming assays using BM from Cbx8 f/f and 
Cbx8 ∆/∆ mice. The data included 4 independent experiments per genotype (bars 
represent mean + SD; n=3 plate/experiment). (C) Representative INT-stained CFU in 
methylcellulose. 




Working Model of Cbx8-Dependent MLL-AF9 Leukemogenesis 
In this study, we investigated the role of CBX8 in MLL-AF9-induced 
leukemogenesis. We have uncovered a novel mechanism involving the HAT 
TIP60 that contributes to MLL-AF9 transcriptional activation and transformation 
but appears dispensable for normal hematopoiesis therefore establishing CBX8 
as an essential cofactor required for MLL-AF9-induced transcriptional activation 




Figure 2.32 Schematic Model Illustrating Role of CBX8 in Promoting MLL-AF9-
Induced Leukemogenesis Top: recruitment of WT MLL is required for transcriptional 
regulation of Hox gene expression in HSCs and early progenitor cells. Left: During 
normal hematopoiesis, Hox gene expression decreases due to the transcriptional 
repression of Polycomb Group proteins. Right: In MLL-AF9 leukemic cells, CBX8 
interacts with MLL-AF9 at the target gene loci and functions as a crucial cofactor 





Potential Broad Role of CBX8 in MLL-Rearranged Leukemogenesis 
CBX8 is one of the five human homologs of the Drosophila Pc protein. Although 
all CBX proteins share highly conserved chromodomains and Pc boxes, their 
different sizes and the presence of other motifs suggest potentially different 
functions (Whitcomb et al., 2007). Indeed, previous studies have reported that 
mice deficient for different PRC1 components show only a partial overlap in 
phenotype, raising the possibility of PRC1-independent functions of these 
components that may be context dependent and involve other protein complexes 
(de Napoles et al., 2004; Katoh-Fukui et al., 1998; Leeb and Wutz, 2007; Suzuki 
et al., 2002; Voncken et al., 2003). Our study has uncovered such a PRC1-
independent function of CBX8 in MLL-AF9-induced transcriptional regulation. 
Interestingly, contrary to its role as a transcriptional repressor in PRC1, CBX8 
serves as a transcriptional coactivator in the MLL-AF9 complex. Furthermore, 
CBX8 is present in the EAP (or the related AEP and the Dotcom) transcriptional 
activation complex (Mohan et al., 2010b; Monroe et al., 2010; Yokoyama et al., 
2010), and our data show that it is also required for the leukemic transformation 
induced by MLL-ENL, another EAP-interacting MLL fusion protein, suggesting 
that the CBX8-dependent leukemogenic mechanism may apply to not only MLL-
AF9 but also other MLL fusion proteins whose fusion partners are present in the 
EAP complex.  
The drastic effect of Cbx8 deletion on leukemogenic capacity of MLL-AF9 and 
MLL-ENL prompted us to ask whether this “Cbx8 addition” is further adopted by 
the MLL fusion proteins with translocation partners absent in the EAP complex, 
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such as MLL-GAS7. BMT assays in the Cbx8 conditional knockout system was 
again used to address this question. Interestingly, an intermediate phenotype 
was observed in this case. To be more specific, we observed a decrease in the 
colony numbers with both pre-transformation excision and post-transformation 
Cbx8 excision (Figure 2.33). However, there were still compact colonies growing 
out upon Cbx8 depletion, which was significantly different from the phenotype in 




Figure 2.33 Effect of Cbx8 Deletion on Leukemogenic Transformation Induced by 
MLL-GAS7 (A and B) Relative CFU of MLL-ENL-transduced cells in the two 
experimental settings. Error bars represent ± SD from two independent experiments. 
Each experiment was performed in duplicate. 
 
Because it has been known that the in vivo leukemogenesis ability of MLL-GAS7 
is not as potent as MLL-AF9 in mouse models, it is technically difficult to 
vigorously elucidate the significance of this intermediate effect in vivo. At this 
point, we do not have a clear mechanistic explanation for this finding. Further 
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detailed studies are certainly required to fully understand this phenotype. 
Although it would be premature to draw a definitive conclusion regarding the role 
of Cbx8 in MLL-GAS7 leukemogenesis based on the current findings, our 
observation does imply a broader role of CBX8 in MLL-rearranged 
leukemogenesis, of which the potential differential mechanisms warrant further 
exploration. 
PRC1-Independent CBX8 Addition of MLL-AF9  
A significant body of work has suggested the involvement of PRC1 components 
in regulating hematopoietic function and hematopoietic malignancies (Bracken 
and Helin, 2009; Martin-Perez et al., 2010; Mills, 2010). Especially, a key 
component of CBX8-containing PRC1 complex, BMI1, is shown to be important 
for normal and leukemic hematopoietic stem cells, in part by repressing the 
INK4a/ARF pathway (Schuringa and Vellenga, 2010). However, consistent with 
our observations, a recent study showed that Bmi1 is not required for MLL-AF9-
induced leukemogenesis (Smith et al., 2011), which, together with our findings, 
further supports the conclusion that the requirement of CBX8 for MLL-AF9 
leukemogenesis is independent of PRC1. Given the finding that CBX8 is involved 
in the INK4a/ARF transcriptional repression by PRC1 in fibroblasts (Dietrich et al., 
2007), it is critical to address whether this mechanism is involved in the CBX8 
addition of MLL-AF9 leukemic cells shown in our data. We therefore examined 
the impact of Cbx8 on INK4a/ARF expression by RT-PCR in MLL-AF9 leukemic 
cells. We found neither Cbx8 downregulation/depletion nor Tip60 downregulation 
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led to INK4a/ARF activation (Figure 2.34), confirming that the CBX8-dependent 




Figure 2.34 Ink4a/Arf Expression Is not Activated upon Cbx8 Downregulation or 
Depletion or upon Tip60 Downregulation (A) RT-PCR analysis of Ink4a/Arf 
expression in MLL-AF9-transformed leukemic cells with shCbx8 transduction compared 
to the control (shScram). (B) RT-PCR analysis of Ink4a/Arf expression in MLL-AF9-
transformed leukemic cells from Cbx8 f/f; Cre+ and Cbx8 f/f; Cre-  mice, with 4-OHT 
treatment compared to the control (EtOH). (C and D) RT-PCR analysis of Ink4a/Arf 
expression in MLL-AF9-transformed leukemic cells with Tip60 knockdown by two 





TIP60 as the First HAT Associated with the MLL-AF9 Complex 
In addition to the MLL fusion partners, CBX8 has previously been shown to 
directly interact with the HAT TIP60, a core member of the MYST family (Stelzl et 
al., 2005). Several TrxG complexes are known to recruit HATs during normal 
development. For example, another core member of the MYST family, MOF 
(MYST1), has been purified in WT MLL complex, and the HAT CREB-binding 
protein (CBP) is known to interacts with both MLL and another TrxG protein 
ASH1 (Bantignies et al., 2000; Dou et al., 2005; Ernst et al., 2001; Petruk et al., 
2001). Under normal physiological conditions, HATs function as a coactivator to 
facilitate TrxG-induced transcriptional activation, antagonizing the transcriptional 
repressive effect of the PcG complex (Mills, 2010; Pasini et al., 2010). This 
mechanism contributes to the active HOXA9 expression in hematopoietic stem 
cells and early progenitors (Figure 2.32). In addition, another two MYST proteins, 
MOZ (MYST3) and MORF (MYST4), are directly involved in chromosomal 
translocations in AML to form chimeric fusion proteins with CBP and/or p300 that 
lead to leukemogenesis (Katsumoto et al., 2008; So and van der Reijden, 2008). 
Moreover, MLL is fused to CBP or P300 in a subset of acute leukemias (Wang et 
al., 2005). Together, multiple lines of evidence have established the critical 
cooperation between MLL physiological function and HAT activity and the pro-
oncogenic role of certain MYST family members in human myeloid leukemias. 
However, previous studies have not reported HATs as a component of the EAP 
complex, which is recruited by the most common MLL fusion partners. Therefore, 
whether HATs contribute to transcriptional activation induced by common MLL-
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rearranged oncoproteins remains unknown. Our finding of the CBX8-dependent 
TIP60 localization at the HOXA9 promoter indicates that this transcriptional 
activation mechanism is likely to be adopted by common MLL fusion proteins to 
activate target gene expression, such as HOXA9. Interestingly, a previous RNAi 
screening study in mouse embryonic stem cells (ESCs) has reported that Tip60 
is required for pluripotency, while MLL myeloid leukemia stem cells have been 
shown to share the transcriptional program with ESCs, rather than adult stem 
cells (Fazzio et al., 2008; Somervaille et al., 2009). Together, these observations 
suggest a possible functional association between the TIP60-regulated signaling 
network and the transcriptional program in MLL-rearranged leukemic cells, 
therefore further supporting our model that CBX8 is essential for MLL-AF9-
induced oncogenic transformation, likely through its interaction with TIP60 at the 
target gene loci to help establish the transcriptional program required for 
leukemogenesis (Figure 2.32). Furthermore, this study, together with previous 
findings, reveals an intriguing mechanistic similarity between WT MLL and 
oncogenic MLL fusion proteins. Specifically, the synergistic activity between HMT 
(H3K4me3) and HAT in transcriptional activation by WT MLL is dependent on the 
C-terminal SET domain, which is absent in MLL fusion proteins as a result of 
translocations. However, oncogenic MLL fusion proteins regain this classic 
combination of enzymatic activities by recruiting another HMT that facilitates 
gene transcription, DOT1L (Bernt et al., 2011; Jo et al., 2011; Nguyen et al., 
2011), and an HAT with a high structural similarity of MOF, TIP60 (Figure 2.35), 
thereby nicely reinforcing the concept of cancer cells hijacking the regulatory 
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mechanisms of normal physiological functions, which have been proven efficient 




Figure 2.35 Comparison of the Key Enzymatic Components between Wild-Type 
MLL and Common MLL-Fusion Proteins. 
 
Therapeutic Implications 
Our identification of the critical role of the CBX8/MLL-AF9 interaction in 
leukemogenesis is of particular therapeutic values, in part because of the striking 
observations that the complete loss of Cbx8 in mice showed no apparent effect 
on viability or hematopoiesis, and that Cbx8-/- BM cells exhibits no apparent 
disadvantage in hematopoietic reconstitution, compared to WT cells. These 
findings suggest an attractive therapeutic window for targeting CBX8 to treat 
MLL-rearranged leukemias. More specifically, developing small molecule 
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inhibitors disrupting the CBX8/AF9 interaction may be a particular promising 
approach. Moreover, the characterization of the CBX8/TIP60 interaction and its 
contribution in MLL-AF9 leukemogenesis suggests that it may be worthwhile to 
explore the therapeutic potential of targeting this interaction. Notably, although 
development and reproduction of Tip60 wild-type and heterozygous mice were 
normal, homozygous ablation of the Tip60 gene caused embryonic lethality near 
the blastocyst stage of development in mice (Hu et al., 2009). Given the broad 
involvement of TIP60 in multiple important biological processes, directly targeting 
TIP60 may raise the issue of toxicity, in which case careful assessment is 
certainly required to evaluate the possible side effects. Nonetheless, the 
essentially null phenotype of Cbx8 knockout mice suggests that this interaction is 
unlikely to be critical for the major function of TIP60. Therefore, specific 
disruption of the CBX8/TIP60 interaction might still be an interesting angle for 
tackling MLL-rearranged leukemias. 
Remaining Questions 
Several important questions remain to be addressed for both better 
understanding the biology of MLL-rearranged leukemias and further exploring the 
clinical application potential of our current findings. First and foremost, it is not 
yet known which domains or regions in CBX8 are responsible for its role in MLL-
AF9-induced leukemogenesis. To address this question, two directions are worth 
exploring. On the one hand, mapping the critical domains, or amino acids, of 
CBX8 that are important for CBX8/AF9 and CBX8/TIP60 interactions is of prior 
importance. A previous study has indicated that Cbx8 binds AF9 within a region 
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of approximately 130 amino acids that is not conserved in other Polycomb 
proteins (Hemenway et al., 2001). However, this region is obviously too broad for 
therapeutic targeting. Generating CBX8 mutants containing small fragment 
deletions and point mutations in this region may narrow down the interest to a 
limited region that is suitable for the binding of small molecule inhibitors. 
Additionally, single amino acid substitution analyses may reveal the key amino 
acids required for the CBX8/AF9 interaction. Small peptides containing the 
corresponding sequences may be used to design dominant negative inhibitors. 
Similar strategies can also be applied to identify the key element of CBX8 for the 
CBX8/TIP60 interaction. On the other hand, characterizing the role of the CBX8 
chromodomain in this particular case is of significant value. Chromodomains are 
present in many chromatin regulatory proteins and are thought to mediate 
interaction with methylated histone lysines or RNA molecules (Akhtar et al., 2000; 
Sapountzi et al., 2006; Utley and Cote, 2003). The chromodomains of Pc 
proteins are thought to, at least in part, localize the proteins and their respective 
complexes to appropriately marked sites of the epigenome through 
reorganization of either H3K9me3 or H3K27me3, both of which indicate 
transcriptional repression (Kaustov et al., 2011). However, despite the high 
degree of conservation among the Pc protein chromodomains, previous studies 
have shown that they display significant differences in histone peptide binding 
preferences (Bernstein et al., 2006; Kaustov et al., 2011). Specifically, the CBX8 
chromodomain has been shown to display essentially no binding preference to 
either H3K9me3 or H3K27me3, and alternative non-histone sequences are 
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suggested as potential binding targets for this chromodomain (Bernstein et al., 
2006; Kaustov et al., 2011).  Therefore, it is intriguing to test whether the CBX8 
chromodomain represents a diverged evolutionary direction of Pc 
chromodomains, which is opposite of their traditional transcription repression role. 
Most importantly, the structure of the CBX8 chromodomain has been well-
characterized, including the potential peptide binding pocket (Kaustov et al., 
2011), which has laid a solid foundation for potential small molecule inhibitor 
development. 
Second, based on our findings so far, it is not yet clear what are the exact 
molecular events responsible for the contribution of TIP60 in MLL-AF9-induced 
leukemogenesis. On one hand, the specificity of the CBX8-affected TIP60 
binding in MLL-AF9 leukemic cells warrants further investigation. For instance, 
ChIP-seq analysis of the binding pattern of Tip60 in the genome of MLL-AF9 
leukemic cells, particularly at MLL-AF9 target loci, in the presence or absence of 
Cbx8, will be helpful to better understand that, to what extent, Cbx8 may affect 
the binding of Tip60. This information will be important for further investigation on 
whether TIP60 may contribute to MLL-AF9 leukemogenesis through both CBX8-
dependent and CBX8-independent mechanisms.  
On the other hand, it will be useful to identify the critical region of TIP60 required 
for the CBX8/TIP60 interaction using the mutagenesis approach previously 
mentioned. Interestingly, TIP60 also contains a chromodomain, and it may have 
yet unidentified functions other than the traditionally characterized interaction 
with histone or RNA molecules (Akhtar et al., 2000; Sapountzi et al., 2006; Utley 
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and Cote, 2003). Apart from the chromodomain, TIP60 contains an MYST 
domain that is highly conserved among MYST family members. It will also be 
important to define the role of this particular domain in the CBX8/TIP60 
interaction because it may shed light on the possibility of specific targeting this 
interaction. In addition to defining the functional domains, identifying the 
downstream events of TIP60 recruitment to the target gene loci is also critical for 
revealing its exact role in MLL-AF9 leukemogenesis. Several potential 
mechanisms may account for this role. (1) TIP60 recruitment may facilitate 
histone acetylation at MLL-AF9 target gene loci, loosing up the chromatin 
structure, thereby promoting transcriptional activation. (2) Given the broad 
spectrum of substrates of TIP60-mediated acetylation, it is possible that TIP60 
acetylates other components of the MLL-AF9 complex to activate their function, 
which contributes to the activation of the whole complex and induces 
leukemogenesis. However, this possible leukemogenic mechanism relies on a 
prerequisite that at least one of the transcription co-activators in the ML-AF9 
complex is regulated by acetylation-dependent activation, whereas none of these 
co-factors have been previously identified as the substrates of TIP60 
acetyltransferase activity. Therefore, much work is still required to directly 
address this potential mechanism. (3) Proteomic studies of the acetylome in 
human cells indicate that proteins involved in chromatin biology are frequent 
targets of acetylation, including histone modifiers and subunits of ATP-dependent 
chromatin remodelers (Choudhary et al., 2009; Sapountzi and Cote, 2011). In 
fact, TIP60 itself, together with several TIP60-interacting partners, has been 
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shown to be acetylated in vivo (Choudhary et al., 2009; Kim et al., 2006), raising 
the possibility of autoacetylation as a potential mechanism of autoregulation. 
Indeed, a recent report has shown that TIP60 is autoacetylated on lysines, and 
that this modification autoregulates its histone acetylation activity (Wang and 
Chen, 2010). It is not yet known whether this autoregulation plays a role in the 
MLL-AF9 complex. The answer to this question will be helpful for fully 
deciphering the enzymatic activities required for MLL-AF9-induced transcriptional 
activation.  
Third, it is of both mechanistic and therapeutic values to explore the specificity of 
TIP60 requirement for MLL-AF9 leukemogenesis. To this end, we knocked down 
the Tip60 expression by shRNA in E2A-HLF leukemic cells, and observed no 
significant changes in colony formation capacity of these cells, therefore 
suggesting at least some extend of specificity of the TIP60 function in the context 
of MLL-AF9 fusion protein (Figure 2.36). It is worth mentioning that we do not 
consider these data to be sufficient for arguing the same significance of TIP60 as 
that of CBX8, in part because of the moderate knockdown efficiency. 
Nevertheless, further detailed characterization in a Tip60 conditional knockout 
mouse model is warranted to better address this question in a clean genetic 
background.  
Fourth, our results indicate that there may be at least two CBX8-associated 
complexes, a CBX8-containing PRC1 and a CBX8-TIP60-containing complex, 
with opposing functions on transcriptional regulation. The PRC1 complex has 
been well studied, whereas extensive biochemical analysis is still required to 
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characterize the composition of the latter in order to fully understand its activity. 
Furthermore, the kinetics assessment of the dynamics between these two 
complexes in the presence of MLL fusion proteins may provide valuable 





Figure 2.36 Knockdown of Tip60 Does not Affect the Transformation of E2A-HLF 
Leukemic Cells (Left) RT-qPCR showing the Tip60 knockdown efficiency in E2A-HLF 
leukemic cell line with shTip60 transduction compared to the control (Scram). Error bars 
represent ± SD. (Middle) Relative CFU of E2A-HLF leukemic cells transduced with 
shTip60, compared to the control (Scram). Error bars represent ± SD. (Right) INT-
stained colonies form shTip60-transduced E2A-HLF cells, compared to the control 
(Scram). 
 
Last but not least, our data demonstrate that CBX8 is necessary for MLL-AF9 
leukemogenesis, despite that it does not seem to affect the localization of MLL-
AF9 to its target gene loci or to be required for the recruitment of the EAP 
complex. This result suggests that additional key activity for MLL-AF9-induced 
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transcriptional activation is yet to be identified. Although our finding regarding 
TIP60 suggests that acetylation activity may be part of the answer, it does not 
rule out the possibility that in addition to TIP60, other co-factors may be involved 
in the dependence of MLL-AF9 leukemogenesis on CBX8 as well. Thus, future 
unbiased analysis is of importance to compare the global changes in gene 
expression and protein-protein interactions in the presence or absence of CBX8 
to fully decipher the leukemogenic mechanisms of MLL-AF9.  
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Chapter 3  
Concluding Remarks 
Chromosome translocations at the MLL locus that generate chimeric MLL fusion 
proteins are one of the major genetic lesions leading to human acute leukemias. 
Although aberrant target gene activation is known as the primary drive of MLL-
rearranged leukemogenesis, the underlying mechanisms remain poorly 
understood. Multiple lines of evidence have indicated that both the N-terminal 
MLL portion and the C-terminal translocation partners of MLL fusion proteins 
bear functional significance. The work described in this thesis explored molecular 
mechanisms that can help decipher this significance and identified novel co-
factors of both the N terminus and the C terminus of MLL fusion proteins, which 
are critical for leukemogenesis. The key findings are summarized as following: 
For the N-terminal MLL portion: 
• PAFc interacts with the pre-CxxC and RD2 domains of MLL 
• Transcriptional activity of MLL and MLL fusion proteins is stimulated by 
PAFc 
• MLL fusion protein mediated transformation is dependent upon interaction 
with PAFc 




For the C-terminal translocation partners (AF9/ENL): 
• CBX8 is essential for both initiation and maintenance of MLL-AF9 
transformation 
• CBX8 is crucial for MLL-AF9-induced transcriptional activation 
• Role of CBX8 in MLL-AF9 leukemogenesis is Independent of PRC1 
• CBX8 regulation of TIP60 localization contributes to MLL-AF9 
transformation 
These observations were primarily obtained using the common fusion proteins 
MLL-AF9 and MLL-ENL. Because of the diversity of MLL fusion partners and the 
elusive leukemogenic mechanisms for many of the less frequent MLL fusion 
proteins (Martin et al., 2003; So et al., 2003), it is yet to be evaluated that to what 
extend our findings can apply to these other fusion proteins. Nevertheless, this 
study has helped reveal a sophisticated oncogenic system orchestrated by MLL 
fusion proteins: the oncoproteins promote constitutive transcriptional activation 
by both hijacking the basal transcriptional machinery (e.g., PAFc) and recruiting 
the co-factor whose functional significance seems rather context-dependent (e.g., 
CBX8, evidenced by its dispensable role in normal hematopoiesis). Moreover, it 
well exemplifies how the oncogenic variants (MLL fusion proteins) of a wild-type 
protein (MLL) rewire the evolutionarily conserved functional collaboration of 
enzymatic activities (HMT-HAT for transcriptional activation: SET and MOF for 
MLL vs. DOT1L and TIP60 for MLL-AF9) for oncogenic purposes.  
Taken together, our observations implicate two potential directions for 
therapeutic application. On the one hand, for the co-factors with critical 
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physiological functions in normal cells, such as PAFc, it is worthwhile to define 
the specificity of their importance in the context of MLL-rearranged leukemias, 
therefore exploring the therapeutic window for preferentially eliminating leukemia 
cells by targeting these factors. On the other hand, for the co-factors whose roles 
are highly context-dependent, such as CBX8, it is of great value to identify their 
differential interaction partners in specific pathogenic processes and to 
characterize the interaction surface and binding kinetics, which in turn lays a 
critical foundation for designing small molecular inhibitors to specifically target 
protein-protein interactions. In summary, this work has presented valuable 
substrates for employing these approaches to further explore novel therapeutic 
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